pamidronate has been researched along with Bone Cancer in 356 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previous studies suggest switching from pamidronate to a more potent bone-targeted agent is associated with biomarker and palliative response in breast cancer patients with bone metastases." | 9.22 | A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. ( Bouganim, N; Cella, D; Clemons, M; Dent, S; Dranitsaris, G; Gertler, S; Jacobs, C; Kuchuk, I; Mazzarello, S; Simos, S; Smith, S; Song, X; Vandermeer, L; Verma, S, 2016) |
| "This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma." | 9.15 | Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. ( Abramson, SJ; Chou, AJ; Gorlick, R; Healey, JH; Kellick, MG; Laquaglia, MP; Merola, PR; Meyers, PA; Morris, CD; Wexler, LH, 2011) |
| "Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety." | 9.13 | [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. ( Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH, 2008) |
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 9.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| "This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate." | 9.12 | Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006) |
| " zoledronic acid with pamidronate treatment in patients with bone metastases from breast cancer or multiple myeloma." | 9.12 | Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR, 2007) |
| "Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial." | 9.11 | Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004) |
| "We studied women with metastatic breast cancer receiving zoledronic acid or pamidronate disodium to reduce the incidence of skeletal-related events (SREs)." | 9.11 | Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. ( Castel, LD; Glendenning, GA; Li, Y; Schulman, KA; Timbie, JW; Weinfurt, KP, 2004) |
| "Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis." | 9.11 | [Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004) |
| "To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis." | 9.11 | [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005) |
| "Results of a large, randomized, comparative phase III trial involving 1,130 breast cancer patients demonstrated that 4 mg zoledronic acid and 90 mg pamidronate were equally effective at reducing the occurrence and delaying the onset of skeletal-related events in patients with bone metastases secondary to breast cancer." | 9.10 | Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. ( Coleman, RE, 2002) |
| "The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma." | 9.10 | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. ( Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ, 2003) |
| " There were no sustained significant differences between the pamidronate and placebo groups in self-reported pain measurements, analgesic use, proportion of patients with an SRE, or mobility at week 9 or 27." | 9.10 | Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. ( Kowalski, MO; Petrone, S; Seaman, JJ; Small, EJ; Smith, MR, 2003) |
| "The aim of this double-blind, randomized study was to compare the effects of two pamidronate dosages, given as repeated infusions in patients with advanced malignant osteolytic bone disease and bone pain." | 9.09 | Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. ( Bacchus, L; Koeberle, D; Senn, HJ; Thuerlimann, B, 1999) |
| "A group of 38 female patients with advanced breast cancer experiencing the first occurrence of tumour-induced hypercalcaemia (TIH), mostly with osteolytic progressive bone metastases, were included in a prospective calcaemia-adapted study using three different doses of pamidronate (30 mg, 45 mg and 60 mg)." | 9.08 | Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia. ( Mitrović, L; Nesković-Konstantinović, Z; Petrović, J; Ristović, Z; Stamatović, L, 1995) |
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 9.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| " 40 patients with progressing painful bone metastases received 45 mg pamidronate by 1-h infusion every 3 weeks." | 9.08 | Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E, 1996) |
| "The effect of pamidronate treatment on the first development of bone metastases was investigated in 124 patients with breast cancer, with either locally advanced disease (n = 33) or extraskeletal metastases (n = 91), but no bone metastases in a randomised, multicentre, open controlled study." | 9.08 | Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? ( Beex, LV; Blijham, G; Cleton, FJ; Hermans, J; Papapoulos, SE; Sleeboom, HP; van Eck-Smit, BC; van Holten-Verzantvoort, AT, 1996) |
| "Breast cancer patients with bone metastases were randomly allocated to receive chemotherapy alone (152 patients) or chemotherapy plus pamidronate 45 mg in 250 mL of saline as a 1-hour intravenous infusion every 3 weeks (143 patients)." | 9.08 | Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. ( Bonneterre, J; Calabresi, F; Campos, D; Conte, PF; Ford, JM; Francini, G; Latreille, J; Mauriac, L; Santos, R, 1996) |
| "Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles." | 9.08 | Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Hortobagyi, GN; Knight, RD; Lipton, A; Porter, L; Seaman, J; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1996) |
| "The superiority of pamidronate in controlling hypercalcemia is mirrored by the changes observed in these markers." | 9.08 | Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1997) |
| "47 patients with progressive, painful, predominantly lytic bone metastases from breast cancer were included in a randomised double-blind phase II trial comparing the effects of pamidronate 150 and 300 mg daily." | 9.08 | A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. ( Coleman, RE; Ford, J; Houston, S; Kandra, A; Purohit, OP; Rubens, RD, 1998) |
| " Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial." | 9.07 | Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994) |
| "An open, randomized study was performed to assess the effects of supportive pamidronate treatment on morbidity from bone metastases in breast cancer patients." | 9.07 | Palliative pamidronate treatment in patients with bone metastases from breast cancer. ( Beex, LV; Bijvoet, OL; Blijham, G; Cleton, FJ; Hermans, J; Kroon, HM; Neijt, JP; Papapoulos, SE; Sleeboom, HP; van Holten-Verzantvoort, AT, 1993) |
| "A total of 295 patients with lytic bone metastases from breast cancer were randomized to receive chemotherapy or chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks." | 9.07 | Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. ( Calabresi, F; Conte, PF; Ford, JM; Giannessi, PG; Koliren, L; Latreille, J; Mauriac, L, 1994) |
| "We therefore initiated an open study with disodium pamidronate (45 mg infused over 1 h and repeated every 21 days) in patients with bone metastases from breast cancer pretreated with chemotherapy and/or hormonetherapy." | 9.07 | Disodium pamidronate in the treatment of bone metastases from breast cancer. ( Bajetta, E; Bochicchio, AM; Colleoni, M; Nolè, F, 1993) |
| "Selective aspects of quality of life during supportive pamidronate (APD) treatment were assessed in breast cancer patients with osteolytic metastases." | 9.07 | The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. ( Aaronson, NK; Bijvoet, OL; Cleton, FJ; Hermans, J; van Dam, FS; van den Bos, B; van Emmerik, B; van Holten-Verzantvoort, AT; Zwinderman, AH, 1991) |
| "The American Society of Clinical Oncology recommends bisphosphonate use, such as intravenous pamidronate, for women with breast cancer who have radiographic evidence of bone destruction." | 8.85 | Pamidronate-induced kidney injury in a patient with metastatic breast cancer. ( Nagahama, M; Sica, DA, 2009) |
| "This is a case report of a patient who developed severe, irreversible hypocalcemia after receiving one dose of pamidronate 90 mg for hypercalcemia of malignancy." | 7.91 | A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy. ( Kim, S, 2019) |
| "After observing metaphyseal changes in pediatric and young adult patients with osteosarcoma who were treated with pamidronate, we initiated a retrospective study to identify bone findings on computed radiography of the chest and extremities, chest CT, extremity MRI, and radionuclide bone scans in this population." | 7.77 | Skeletal imaging effects of pamidronate therapy in osteosarcoma patients. ( Abramson, SJ; Bartolotta, R; Chou, A; Hwang, S; Katz, DS; Meyers, P; Price, AP, 2011) |
| "To evaluate in vitro biological activity of gemcitabine, alone and in combination with Pamidronate or carboplatin, against canine osteosarcoma (OSA) cell lines." | 7.76 | Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. ( Bear, MD; Kulp, SK; London, CA; McMahon, MB; Pennell, ML, 2010) |
| " We present here the first case of an acute retinal pigment epithelial detachment associated with pamidronate infusion in a 59-year-old patient with metastatic prostate cancer." | 7.75 | Acute retinal pigment epithelial detachment secondary to pamidronate administration. ( Alexandrescu, DT; Dasanu, CA, 2009) |
| "We report on our experience with 13 cases of jaw osteonecrosis in patients treated with amino-bisphosphonates." | 7.74 | Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. ( Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH, 2008) |
| " We collected resource use data prospectively for 930 patients alongside a multinational trial of zoledronic acid versus pamidronate for patients with metastatic multiple myeloma or breast cancer and > or =1 bone lesion." | 7.73 | Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. ( Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA, 2005) |
| " generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i." | 7.73 | Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks." | 7.73 | Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005) |
| "The aim of this study was to compare the cost-effectiveness of oral ibandronate with zoledronic acid and generic pamidronate (both administered by IV) for the treatment of bone metastases in patients with breast cancer receiving oral hormonal therapy in the United Kingdom." | 7.73 | Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "The Japanese Ministry of Health, Labor and Welfare approved the use of pamidronate in November 2004 at a dose of 90 mg/day/month especially for Japanese breast cancer patients with lytic bone metastasis." | 7.73 | [Retrospective evaluation of the safety of pamidronate administration at the dose of 90 mg/day/month in Japanese breast cancer patients with bone metastasis]. ( Aogi, K; Ohsumi, S; Okita, A; Taira, N; Takashima, S, 2006) |
| " When conventional treatment of hypercalcemia failed, pamidronate dramatically decreased both the calcium levels and the frequency of uterine contractions." | 7.73 | Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. ( Culbert, EC; Schfirin, BS, 2006) |
| "Tartrate-resistant acid phosphatase isoform-5b (TRACP-5b), a new marker reflecting osteoclast activity, and osteoprotegerin (OPG) were measured in 121 patients with multiple myeloma (MM) at diagnosis, and in 63 of them during pamidronate administration, to define their correlation with the extent of bone disease and disease activity in MM." | 7.72 | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. ( de la Fuente, J; Goldman, JM; Hatjiharissi, E; Meletis, J; Rahemtulla, A; Szydlo, R; Terpos, E; Viniou, N; Yataganas, X, 2003) |
| "A 62-yr-old woman with thyroid carcinoma metastatic to bone, and a history of subclinical hypoparathyroidism was admitted to the hospital in hypocalcemic crisis 5 wk after receiving iv pamidronate." | 7.71 | Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. ( Jonklaas, J; Mishra, A; Wong, L, 2001) |
| "Our goal was to evaluate the impact of pamidronate therapy on medical resource utilization for treatment of bone metastases among patients with breast cancer." | 7.71 | The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. ( Ackerman, SJ; Beusterien, KM; Hill, MC; Zacker, C, 2001) |
| "Pamidronate is effective in reducing bony complications in patients with metastatic breast cancer who have known osteolytic lesions." | 7.70 | Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. ( Desch, CE; Hillner, BE; Smith, TJ; Weeks, JC, 2000) |
| "Two patients with malignancy-associated hypercalcemia from bone metastases of breast cancer, accompanied by consciousness disturbance, were treated by a combination therapy of pamidronate and salmon calcitonin." | 7.70 | [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Ota, D, 2000) |
| "Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 7.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
| "The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally." | 7.68 | The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. ( Coleman, RE; Daley-Yates, PT; Dodwell, DJ; Howell, A; Pongchaidecha, M, 1991) |
| "28 patients with progressing painful bone metastases (18 breast cancer, 9 myeloma and 1 low grade lymphoma) received pamidronate 60 mg by 24 h continuous infusion for at least 2 courses (range 2-12)." | 7.68 | Treatment of bone metastases from breast cancer and myeloma with pamidronate. ( Burckhardt, P; Cornu, P; Leyvraz, S; Perey, L; Thiébaud, D; Thiébaud, S; von Fliedner, V, 1991) |
| "The bisphosphonate pamidronate (3 amino-1, 1-hydroxypropylidene bisphosphonate (APD), Ciba-Geigy) is a powerful inhibitor of osteoclast function and has been shown to significantly reduce osteolysis associated with bone metastases in breast cancer." | 7.68 | Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. ( Dodwell, DJ; Ford, J; Howell, A, 1990) |
| "Despite substantial variability in individual risk of skeletal complications, patients with metastatic bone disease are treated with bisphosphonates at the same dose and dosing interval." | 6.78 | Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. ( Amir, E; Carlsson, L; Clemons, M; Dranitsaris, G; Freedman, O; Laupacis, A; Tannock, IF; Tomlinson, G, 2013) |
| "Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL)." | 6.71 | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. ( Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD, 2003) |
| "Pamidronate was well tolerated in the majority of the patients both during the first six infusions and during the whole study period." | 6.70 | The role of disodium pamidronate in the management of bone pain due to malignancy. ( Boffi, R; Brunelli, C; Cazzaniga, M; De Conno, F; Groff, L; Panzeri, C; Ripamonti, C; Zecca, E, 2001) |
| "Twenty-five advanced breast cancer patients who were bisphosphonate naYve and had developed skeletal related complications were identified." | 6.69 | Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. ( Dranitsaris, G; Hsu, T, 1999) |
| "Pamidronate is a potent biphosphonate which modulates tumour-induced osteolysis (TIO) by inhibiting osteoclast-mediated bone resorption." | 6.68 | Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer. ( Bruning, PF; Ford, JM; Mauriac, L; May-Levin, F; Rose, C; Soukop, M; Tyrrell, CT, 1995) |
| "Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status." | 6.41 | [Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002) |
| " Review of the published literature suggests that a clinically relevant dose-response relationship exists in the dose range 30-60 mg; most hypercalcemic patients will achieve normocalcemia with a dose of 60 mg pamidronate or more." | 6.39 | Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? ( Thürlimann, B, 1994) |
| "A 15 minute infusion of 4 mg of zoledronic acid is at least as effective as 90 mg of pamidronate in preventing skeletal complications in patients with metastatic breast cancer." | 6.20 | Bisphosphonates and metastatic breast carcinoma. ( Lipton, A, 2003) |
| "BACKGROUND Hypercalcemia is a common complication in the intensive care unit (ICU)." | 5.48 | Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report. ( El Madhoun, I; El Zeer, HS; Khatib, M; Mahmoud, S; Mitwally, H, 2018) |
| " The repeat dosing of Pam-Doxo-NPs in dogs with naturally occurring OS indicated the therapeutic was well tolerated without hematologic, nonhematologic, and cardiac toxicities." | 5.43 | Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. ( Borst, LB; Cai, K; Cheng, J; Dobrucki, LW; Fan, TM; Helferich, WG; Kamstock, D; Song, Z; Sternberg, R; Tang, L; Tong, R; Yang, X; Yin, Q, 2016) |
| "Hypocalcemia is a potential adverse effect of these drugs, which is considered infrequent and rarely symptomatic." | 5.32 | Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports. ( Basuyau, JP; Brunelle, P; Champallou, C; Chevrier, A; Chinet, P; Debled, M; Grongnet, MH; Veyret, C, 2003) |
| "Zoledronic acid also attenuated mechanical hyperalgesia associated with chronic peripheral neuropathy and inflammation in the rat." | 5.31 | Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. ( Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K, 2002) |
| "Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains." | 5.30 | Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998) |
| "Previous studies suggest switching from pamidronate to a more potent bone-targeted agent is associated with biomarker and palliative response in breast cancer patients with bone metastases." | 5.22 | A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer. ( Bouganim, N; Cella, D; Clemons, M; Dent, S; Dranitsaris, G; Gertler, S; Jacobs, C; Kuchuk, I; Mazzarello, S; Simos, S; Smith, S; Song, X; Vandermeer, L; Verma, S, 2016) |
| "This study evaluated the safety and feasibility of the addition of pamidronate to chemotherapy for treatment of osteosarcoma." | 5.15 | Addition of pamidronate to chemotherapy for the treatment of osteosarcoma. ( Abramson, SJ; Chou, AJ; Gorlick, R; Healey, JH; Kellick, MG; Laquaglia, MP; Merola, PR; Meyers, PA; Morris, CD; Wexler, LH, 2011) |
| " This model was applied to the placebo-control arm of a pamidronate study in patients with malignant bone disease from breast cancer." | 5.14 | Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, PP; Smith, MR; Terpos, E, 2009) |
| "Intravenous injection of 4 mg zoledronic acid can significantly reduce bone pain and bone resorption marker in urine in the Chinese patients with bone metastasis from solid tumor or multiple myeloma, which is tolerable and also comparable to pamidronate in the efficacy and safety." | 5.13 | [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma]. ( Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH, 2008) |
| "Patients with either progressive bone metastases or SREs while on clodronate or pamidronate may experience significant pain palliation with a switch to a more potent bisphosphonate." | 5.13 | A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. ( Clemons, M; Cole, DE; Dranitsaris, G; Ooi, W, 2008) |
| "During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures." | 5.13 | Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008) |
| "This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate." | 5.12 | Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006) |
| " zoledronic acid with pamidronate treatment in patients with bone metastases from breast cancer or multiple myeloma." | 5.12 | Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. ( Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR, 2007) |
| "Treatment with zoledronic acid (Zol) was compared with a dose of 90 mg of pamidronate (Pam) in breast carcinoma (BC) patients with at least 1 osteolytic lesion based on data from a Phase III, randomized trial." | 5.11 | Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. ( Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J, 2004) |
| "We studied women with metastatic breast cancer receiving zoledronic acid or pamidronate disodium to reduce the incidence of skeletal-related events (SREs)." | 5.11 | Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. ( Castel, LD; Glendenning, GA; Li, Y; Schulman, KA; Timbie, JW; Weinfurt, KP, 2004) |
| "Data concerning the suspension of new skeletal complications, as well as the apparent improvement of overall survival, pain score and ECOG status, suggest that the pamidronate-treatment should not be stopped once started." | 5.11 | Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer. ( Balafouta, M; Gennatas, C; Kokakis, J; Kouloulias, VE; Kouvaris, JR; Mystakidou, K; Pistevou-Gombaki, K; Varela, MN; Vlahos, LJ, 2004) |
| "Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis." | 5.11 | [Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004) |
| "To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis." | 5.11 | [Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005) |
| "Results of a large, randomized, comparative phase III trial involving 1,130 breast cancer patients demonstrated that 4 mg zoledronic acid and 90 mg pamidronate were equally effective at reducing the occurrence and delaying the onset of skeletal-related events in patients with bone metastases secondary to breast cancer." | 5.10 | Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. ( Coleman, RE, 2002) |
| "The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma." | 5.10 | Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. ( Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ, 2003) |
| " There were no sustained significant differences between the pamidronate and placebo groups in self-reported pain measurements, analgesic use, proportion of patients with an SRE, or mobility at week 9 or 27." | 5.10 | Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. ( Kowalski, MO; Petrone, S; Seaman, JJ; Small, EJ; Smith, MR, 2003) |
| "The aim of this double-blind, randomized study was to compare the effects of two pamidronate dosages, given as repeated infusions in patients with advanced malignant osteolytic bone disease and bone pain." | 5.09 | Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. ( Bacchus, L; Koeberle, D; Senn, HJ; Thuerlimann, B, 1999) |
| "A group of 38 female patients with advanced breast cancer experiencing the first occurrence of tumour-induced hypercalcaemia (TIH), mostly with osteolytic progressive bone metastases, were included in a prospective calcaemia-adapted study using three different doses of pamidronate (30 mg, 45 mg and 60 mg)." | 5.08 | Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia. ( Mitrović, L; Nesković-Konstantinović, Z; Petrović, J; Ristović, Z; Stamatović, L, 1995) |
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 5.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| " 40 patients with progressing painful bone metastases received 45 mg pamidronate by 1-h infusion every 3 weeks." | 5.08 | Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E, 1996) |
| "The effect of pamidronate treatment on the first development of bone metastases was investigated in 124 patients with breast cancer, with either locally advanced disease (n = 33) or extraskeletal metastases (n = 91), but no bone metastases in a randomised, multicentre, open controlled study." | 5.08 | Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients? ( Beex, LV; Blijham, G; Cleton, FJ; Hermans, J; Papapoulos, SE; Sleeboom, HP; van Eck-Smit, BC; van Holten-Verzantvoort, AT, 1996) |
| "Breast cancer patients with bone metastases were randomly allocated to receive chemotherapy alone (152 patients) or chemotherapy plus pamidronate 45 mg in 250 mL of saline as a 1-hour intravenous infusion every 3 weeks (143 patients)." | 5.08 | Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. ( Bonneterre, J; Calabresi, F; Campos, D; Conte, PF; Ford, JM; Francini, G; Latreille, J; Mauriac, L; Santos, R, 1996) |
| "Women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion were given either placebo or pamidronate (90 mg) as a two-hour intravenous infusion monthly for 12 cycles." | 5.08 | Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Hortobagyi, GN; Knight, RD; Lipton, A; Porter, L; Seaman, J; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1996) |
| "The superiority of pamidronate in controlling hypercalcemia is mirrored by the changes observed in these markers." | 5.08 | Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1997) |
| " Anderson, the use of the recently approved bisphosphonate pamidronate (Aredia) became a part of the standard of care pathway for the treatment of osteolytic metastases from breast cancer." | 5.08 | Fitting new modalities into practice guidelines. ( Theriault, RL, 1997) |
| "47 patients with progressive, painful, predominantly lytic bone metastases from breast cancer were included in a randomised double-blind phase II trial comparing the effects of pamidronate 150 and 300 mg daily." | 5.08 | A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. ( Coleman, RE; Ford, J; Houston, S; Kandra, A; Purohit, OP; Rubens, RD, 1998) |
| " Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial." | 5.07 | Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994) |
| "Four intravenous regimens of pamidronate (Aredia) were evaluated for palliative treatment of bone metastases in 2 randomized open-label trials in patients with breast cancer (n = 61) or prostate cancer (n = 58)." | 5.07 | Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer. ( Glover, D; Grabelsky, S; Harvey, H; Lipton, A; Macerata, R; Seaman, J; Zelenakas, K, 1994) |
| "An open, randomized study was performed to assess the effects of supportive pamidronate treatment on morbidity from bone metastases in breast cancer patients." | 5.07 | Palliative pamidronate treatment in patients with bone metastases from breast cancer. ( Beex, LV; Bijvoet, OL; Blijham, G; Cleton, FJ; Hermans, J; Kroon, HM; Neijt, JP; Papapoulos, SE; Sleeboom, HP; van Holten-Verzantvoort, AT, 1993) |
| "A total of 295 patients with lytic bone metastases from breast cancer were randomized to receive chemotherapy or chemotherapy plus pamidronate (Aredia) 45 mg intravenously every 3 weeks." | 5.07 | Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. ( Calabresi, F; Conte, PF; Ford, JM; Giannessi, PG; Koliren, L; Latreille, J; Mauriac, L, 1994) |
| "We therefore initiated an open study with disodium pamidronate (45 mg infused over 1 h and repeated every 21 days) in patients with bone metastases from breast cancer pretreated with chemotherapy and/or hormonetherapy." | 5.07 | Disodium pamidronate in the treatment of bone metastases from breast cancer. ( Bajetta, E; Bochicchio, AM; Colleoni, M; Nolè, F, 1993) |
| "Selective aspects of quality of life during supportive pamidronate (APD) treatment were assessed in breast cancer patients with osteolytic metastases." | 5.07 | The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. ( Aaronson, NK; Bijvoet, OL; Cleton, FJ; Hermans, J; van Dam, FS; van den Bos, B; van Emmerik, B; van Holten-Verzantvoort, AT; Zwinderman, AH, 1991) |
| "Pamidronate can rarely cause (collapsing) focal segmental glomerular sclerosis with the nephrotic syndrome and renal insufficiency." | 4.88 | Renal complications from bisphosphonate treatment. ( Hirschberg, R, 2012) |
| ", oral clodronate and intravenous pamidronate and zoledronic acid) can inhibit osteoclast-mediated osteolysis, thereby reducing the risk of SREs, ameliorating bone pain, and potentially prolonging survival in patients with MM." | 4.87 | Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. ( Berenson, J; Dimopoulos, MA; Terpos, E, 2011) |
| "For more than 10 years, based on the results with the bisphosphonate clodronic acid, it has been discussed, whether the occurrence of breast cancer metastases can be avoided or at least delayed by administration of bisphosphonates." | 4.86 | [Bisphosphonates in adjuvant therapy of breast cancer]. ( Deuber, HJ; Theiss, F, 2010) |
| "The American Society of Clinical Oncology recommends bisphosphonate use, such as intravenous pamidronate, for women with breast cancer who have radiographic evidence of bone destruction." | 4.85 | Pamidronate-induced kidney injury in a patient with metastatic breast cancer. ( Nagahama, M; Sica, DA, 2009) |
| "Zoledronic acid (Zometa is a third-generation nitrogen-containing parenteral bisphosphonate indicated for the treatment of bone metastases due to solid tumours or multiple myeloma and for hypercalcaemia of malignancy (HCM)." | 4.84 | Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases. ( McKeage, K; Plosker, GL, 2008) |
| " They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect." | 4.80 | Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. ( Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD, 1998) |
| " In multiple myeloma, one study with oral clodronate has reported a decrease in bone events and two other studies, one with intravenous pamidronate and the other with oral clodronate have both reported a decrease in skeletal events and bone pain." | 4.80 | [Bisphosphonates and bone metastases]. ( Berthaud, P; Jadaud, E; Lortholary, A, 1999) |
| " As regards pamidronate, several open, controlled studies have shown a significant effect on bone pain in 30-70% of breast cancer patients." | 4.79 | Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. ( Strang, P, 1996) |
| "This is a case report of a patient who developed severe, irreversible hypocalcemia after receiving one dose of pamidronate 90 mg for hypercalcemia of malignancy." | 3.91 | A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy. ( Kim, S, 2019) |
| "Pamidronate is a bisphosphonate drug widely utilized in veterinary oncologic practice for the palliation of malignant osteolysis." | 3.85 | Extravasation reactions associated with the administration of pamidronate: 11 cases (2008-2013). ( Barber, LG; Clifford, CA; Correa, SS; LaDue, TA; Marker, BA; Mullin, CM; Sauerbrey, ML; Thalhofer, PL; Wood, CC, 2017) |
| " Bone cancer was induced by intra-tibial injections of murine mammary carcinoma cells (4T1) in immunocompetent BALB/c mice and treated intraperitoneally for up to 5 weeks with vehicle, rapamycin or pamidronate (a bisphosphonate currently used to reduce bone loss in bone cancer patients)." | 3.80 | Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin. ( Abdelaziz, DM; Komarova, SV; Stone, LS, 2014) |
| "Osteonecrosis of the jaw is an adverse outcome associated with bisphosphonate treatment." | 3.79 | Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study. ( Catalfamo, L; Centofanti, A; Cutroneo, G; De Ponte, FS; Favaloro, A; Runci, M; Siniscalchi, EN, 2013) |
| "Our results show that the majority of patients with breast cancer, who develop bony metastases in Newfoundland and Labrador, are initially treated with the bisphosphonate, pamidronate." | 3.79 | Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. ( Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M, 2013) |
| "After observing metaphyseal changes in pediatric and young adult patients with osteosarcoma who were treated with pamidronate, we initiated a retrospective study to identify bone findings on computed radiography of the chest and extremities, chest CT, extremity MRI, and radionuclide bone scans in this population." | 3.77 | Skeletal imaging effects of pamidronate therapy in osteosarcoma patients. ( Abramson, SJ; Bartolotta, R; Chou, A; Hwang, S; Katz, DS; Meyers, P; Price, AP, 2011) |
| "Bone-modifying agent therapy is only recommended for patients with breast cancer with evidence of bone metastases; denosumab 120 mg subcutaneously every 4 weeks, intravenous pamidronate 90 mg over no less than 2 hours, or zoledronic acid 4 mg over no less than 15 minutes every 3 to 4 weeks is recommended." | 3.77 | American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. ( Barlow, WE; Biermann, JS; Bosserman, LD; Geoghegan, C; Hillner, BE; Janjan, NA; Temin, S; Theriault, RL; Van Poznak, CH; Von Roenn, JH; Yee, GC; Zuckerman, DS, 2011) |
| "The gross volume and mineralization of osteosarcoma lesions were evaluated in living mice simultaneously with dual-channels by NIR dye-labeled probes, 2-deoxyglucose (DG) and pamidronate (OS), respectively." | 3.77 | In-vivo near-infrared optical imaging of growing osteosarcoma cell lesions xenografted in mice: dual-channel quantitative evaluation of volume and mineralization. ( Kawase, T; Nakayama, H; Okuda, K; Wolff, LF; Yoshie, H, 2011) |
| "Pamidronate has a pharmacologic profile similar to that of etidronate, but pamidronate is more potent and has a longer duration of effect." | 3.77 | Pamidronate. ( Kellihan, MJ; Mangino, PD, 1992) |
| "To evaluate in vitro biological activity of gemcitabine, alone and in combination with Pamidronate or carboplatin, against canine osteosarcoma (OSA) cell lines." | 3.76 | Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro. ( Bear, MD; Kulp, SK; London, CA; McMahon, MB; Pennell, ML, 2010) |
| " Osteonecrosis of the jaw is an uncommon but serious event in patients receiving monthly intravenous bisphosphonates or denosumab." | 3.76 | Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. ( Aapro, M; Costa, L; Saad, F, 2010) |
| " We present here the first case of an acute retinal pigment epithelial detachment associated with pamidronate infusion in a 59-year-old patient with metastatic prostate cancer." | 3.75 | Acute retinal pigment epithelial detachment secondary to pamidronate administration. ( Alexandrescu, DT; Dasanu, CA, 2009) |
| "We report on our experience with 13 cases of jaw osteonecrosis in patients treated with amino-bisphosphonates." | 3.74 | Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy. ( Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH, 2008) |
| " We collected resource use data prospectively for 930 patients alongside a multinational trial of zoledronic acid versus pamidronate for patients with metastatic multiple myeloma or breast cancer and > or =1 bone lesion." | 3.73 | Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma. ( Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA, 2005) |
| " generic pamidronate in female breast cancer patients with metastatic bone disease, undergoing i." | 3.73 | Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks." | 3.73 | Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. ( Cremers, SC; den Hartigh, J; Gelderblom, H; Papapoulos, SE; Seynaeve, C; van der Rijt, CC; van Zuylen, L; Vermeij, P, 2005) |
| "The aim of this study was to compare the cost-effectiveness of oral ibandronate with zoledronic acid and generic pamidronate (both administered by IV) for the treatment of bone metastases in patients with breast cancer receiving oral hormonal therapy in the United Kingdom." | 3.73 | Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom. ( Barrett-Lee, P; Body, JJ; Canney, P; De Cock, E; Hutton, J; Lewis, G; Neary, MP, 2005) |
| "Osteonecrosis of the jaw (ONJ) has been associated recently with the use of pamidronate and zoledronic acid." | 3.73 | Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. ( Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E, 2005) |
| "The Japanese Ministry of Health, Labor and Welfare approved the use of pamidronate in November 2004 at a dose of 90 mg/day/month especially for Japanese breast cancer patients with lytic bone metastasis." | 3.73 | [Retrospective evaluation of the safety of pamidronate administration at the dose of 90 mg/day/month in Japanese breast cancer patients with bone metastasis]. ( Aogi, K; Ohsumi, S; Okita, A; Taira, N; Takashima, S, 2006) |
| " When conventional treatment of hypercalcemia failed, pamidronate dramatically decreased both the calcium levels and the frequency of uterine contractions." | 3.73 | Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions. ( Culbert, EC; Schfirin, BS, 2006) |
| "Tartrate-resistant acid phosphatase isoform-5b (TRACP-5b), a new marker reflecting osteoclast activity, and osteoprotegerin (OPG) were measured in 121 patients with multiple myeloma (MM) at diagnosis, and in 63 of them during pamidronate administration, to define their correlation with the extent of bone disease and disease activity in MM." | 3.72 | Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. ( de la Fuente, J; Goldman, JM; Hatjiharissi, E; Meletis, J; Rahemtulla, A; Szydlo, R; Terpos, E; Viniou, N; Yataganas, X, 2003) |
| "Charts and electronic files of breast cancer patients with bone metastases who had received either clodronate or pamidronate at any time between January 2000 and December 2001 at our center were retrospectively reviewed." | 3.72 | Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience. ( Chow, E; Clemons, M; Enright, K, 2004) |
| " Pamidronate, an inhibitor of bone resorption used primarily in the management of tumor-induced hypercalcemia and Paget's disease, is reported to cause conjunctivitis, anterior uveitis, and infrequently episcleritis and scleritis." | 3.72 | Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports. ( Claes, C; Haverbeke, G; Pertile, G; Zeyen, T, 2003) |
| "The most serious, potentially life-threatening manifestation of 'flare' is hypercalcemia, registered in 4-5% of breast cancer patients with bone metastases, usually during the first few weeks of tamoxifen treatment." | 3.71 | Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates? ( Jelic, S; Mitrović, L; Nikolic-Tomasević, Z; Popov, I; Radosavljević, D, 2001) |
| "A 62-yr-old woman with thyroid carcinoma metastatic to bone, and a history of subclinical hypoparathyroidism was admitted to the hospital in hypocalcemic crisis 5 wk after receiving iv pamidronate." | 3.71 | Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. ( Jonklaas, J; Mishra, A; Wong, L, 2001) |
| "Our goal was to evaluate the impact of pamidronate therapy on medical resource utilization for treatment of bone metastases among patients with breast cancer." | 3.71 | The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients. ( Ackerman, SJ; Beusterien, KM; Hill, MC; Zacker, C, 2001) |
| " Thirty-seven patients with newly diagnosed bone metastases from breast cancer, randomized to receive oral pamidronate or placebo tablets in addition to anticancer treatment within the context of a multicentre EORTC trial, who were both assessable for radiographic response in bone and had serum and urine samples collected for more than 1 month were studied." | 3.70 | Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer. ( Bastit, P; Coleman, R; Ford, J; Lacombe, D; Leonard, R; Michel, J; Mignolet, F; Nortier, J; Rose, C; Tubiana-Hulin, M; Vinholes, J; Wildiers, J, 1999) |
| "Pamidronate is effective in reducing bony complications in patients with metastatic breast cancer who have known osteolytic lesions." | 3.70 | Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. ( Desch, CE; Hillner, BE; Smith, TJ; Weeks, JC, 2000) |
| "Two patients with malignancy-associated hypercalcemia from bone metastases of breast cancer, accompanied by consciousness disturbance, were treated by a combination therapy of pamidronate and salmon calcitonin." | 3.70 | [Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Ota, D, 2000) |
| " Pamidronate (Aredia(TM)) is the most widely evaluated bisphosphonate and is recommended for most patients with multiple myeloma or breast cancer with bone metastases." | 3.70 | Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM). ( Coleman, RE, 2000) |
| "We reviewed our experience with pamidronate in 160 patients with tumour-induced hypercalcemia (TIH) persisting after rehydration, particularly the influence of the dose administered, the tumour type and the presence of bone metastatic involvement on the calcaemic and calciuric response to pamidronate therapy." | 3.69 | Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. ( Body, JJ; Dumon, JC, 1994) |
| " One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis." | 3.69 | Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995) |
| "Autopsy specimens of a bone metastasis from a woman with a primary squamous cell carcinoma of the tongue who developed multiple osteolytic lesions and hypercalcemia and was treated with pamidronate were studied histologically, histochemically, and ultrastructurally." | 3.69 | Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastasis of a squamous cell carcinoma: report of an autopsy case and evaluation of bone resorbing activity in an experimental animal model. ( Hiraga, T; Nakajima, T; Ozawa, H; Takada, M, 1996) |
| "Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 3.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
| " We compared several new markers of bone turnover in normocalcaemic patients with breast cancer-induced osteolysis before and after a single infusion of the bisphosphonate pamidronate." | 3.69 | Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. ( Body, JJ; Delmas, PD; Dumon, JC; Gineyts, E, 1997) |
| " We performed a clinical study to evaluate the therapeutic effect of Disodium Pamidronate over pain and radiologic evolution in bone metastases (Breast Cancer and Multiple Myeloma patients)." | 3.68 | [Disodium pamidronate (APD) in the treatment of bone metastases]. ( Costa, L; da Costa, EB; Moreira, C, 1993) |
| " The urinary excretion of these compounds, expressed as a ratio to urinary creatinine, has been measured using ion-pair reversed phase high-performance liquid chromatography in 20 patients receiving oral pamidronate for bone metastases from breast cancer." | 3.68 | Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. ( Coleman, RE; Ford, J; Houston, S; James, I; Leonard, RC; Rodger, A; Rubens, RD, 1992) |
| "The pharmacokinetics and bioavailability of pamidronate were assessed in patients with breast cancer, 6 subjects received the drug intravenously and 7 orally." | 3.68 | The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases. ( Coleman, RE; Daley-Yates, PT; Dodwell, DJ; Howell, A; Pongchaidecha, M, 1991) |
| "28 patients with progressing painful bone metastases (18 breast cancer, 9 myeloma and 1 low grade lymphoma) received pamidronate 60 mg by 24 h continuous infusion for at least 2 courses (range 2-12)." | 3.68 | Treatment of bone metastases from breast cancer and myeloma with pamidronate. ( Burckhardt, P; Cornu, P; Leyvraz, S; Perey, L; Thiébaud, D; Thiébaud, S; von Fliedner, V, 1991) |
| "The bisphosphonate pamidronate (3 amino-1, 1-hydroxypropylidene bisphosphonate (APD), Ciba-Geigy) is a powerful inhibitor of osteoclast function and has been shown to significantly reduce osteolysis associated with bone metastases in breast cancer." | 3.68 | Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate. ( Dodwell, DJ; Ford, J; Howell, A, 1990) |
| "Bone metastatic disease may lead to serious adverse events in patients with cancer." | 2.82 | Adverse events associated with bone-directed therapies in patients with cancer. ( Hu, MI; Jara, MA; Varghese, J, 2022) |
| "Despite substantial variability in individual risk of skeletal complications, patients with metastatic bone disease are treated with bisphosphonates at the same dose and dosing interval." | 2.78 | Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. ( Amir, E; Carlsson, L; Clemons, M; Dranitsaris, G; Freedman, O; Laupacis, A; Tannock, IF; Tomlinson, G, 2013) |
| " The incidence of febrile adverse reactions from incardronate was significantly lower than pamidronate disodium (OR =0." | 2.72 | Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis. ( He, L; Meng, R; Tang, Z; Wang, Y, 2021) |
| "dose of denosumab given to patients with multiple myeloma or bone metastases from breast cancer was well tolerated and reduced bone resorption for at least 84 days." | 2.72 | A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. ( Bekker, PJ; Body, JJ; Coleman, RE; Facon, T; Fan, M; Geurs, F; Holloway, D; Lipton, A; Peterson, MC, 2006) |
| "Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL)." | 2.71 | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. ( Bekker, PJ; Body, JJ; Coleman, RE; Dunstan, CR; Facon, T; Fermand, JP; Geurs, F; Greipp, P; Harousseau, JL; Holloway, D; Lipton, A; Mariette, X; Martin, SW; Nakanishi, A; Williams, CD, 2003) |
| "Pamidronate was administered as an intravenous infusion, most commonly at a dose of 90 mg monthly." | 2.71 | [Efficacy and feasibility evaluation in long term pamidronate treatment of bone metastases]. ( Jassem, J; Krasińska, L; Krasińska, W; Nowaczyk, M; Pikiel, J; Senkus-Konefka, E, 2003) |
| " Regular Z 4 mg infusions appear to be safe in these patients, with routine monitoring of serum creatinine." | 2.71 | Bisphosphonate infusions: patient preference, safety and clinic use. ( Chern, B; Copeman, M; De Abreu Lourenco, R; Joseph, D; Joshua, D; Lowe, S; Lynch, K; Pittman, K; Richardson, G; Schou, M, 2004) |
| "This study evaluated the dose-response relation for zoledronic acid, a new generation high potency bisphosphonate, given as a 5-minute infusion in patients with malignant osteolytic disease." | 2.70 | Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. ( Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ, 2001) |
| "Skeletal metastases from thyroid cancer are poorly responsive to medical or radioiodine treatment." | 2.70 | Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. ( Abbruzzese, A; Caraglia, M; Ciccarelli, A; Fonderico, F; Lupoli, G; Martignetti, A; Nuzzo, V; Vitale, G, 2001) |
| "Bone resorption was assessed by measurement of urinary collagen crosslinks." | 2.70 | Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. ( Coleman, RE; Heatley, S; Herling, C; Jagdev, SP; Purohit, P, 2001) |
| "Pamidronate was well tolerated in the majority of the patients both during the first six infusions and during the whole study period." | 2.70 | The role of disodium pamidronate in the management of bone pain due to malignancy. ( Boffi, R; Brunelli, C; Cazzaniga, M; De Conno, F; Groff, L; Panzeri, C; Ripamonti, C; Zecca, E, 2001) |
| "Twenty-five advanced breast cancer patients who were bisphosphonate naYve and had developed skeletal related complications were identified." | 2.69 | Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. ( Dranitsaris, G; Hsu, T, 1999) |
| "The treatment with pamidronate reduced pain significantly but did not add noticeably to the costs." | 2.69 | Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. ( Bacchus, L; Gessner, U; Horisberger, B; Koeberle, D; Thuerlimann, B, 2000) |
| "Pamidronate is a potent biphosphonate which modulates tumour-induced osteolysis (TIO) by inhibiting osteoclast-mediated bone resorption." | 2.68 | Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer. ( Bruning, PF; Ford, JM; Mauriac, L; May-Levin, F; Rose, C; Soukop, M; Tyrrell, CT, 1995) |
| "We have evaluated the value of specific bone resorption markers in monitoring metastatic bone disease to define the duration of action of a single high-dose pamidronate infusion." | 2.68 | Metabolic effects of pamidronate in patients with metastatic bone disease. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1996) |
| " In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i." | 2.68 | The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996) |
| "The new bone resorption markers of collagen breakdown were able to predict clinical response to pamidronate." | 2.68 | Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. ( Abbey, ME; Coleman, RE; Eastell, R; Purohit, OP; Vinholes, JJ, 1997) |
| "Treatment with zoledronic acid probably neither reduces nor increases the proportion of participants with pain response when compared to no treatment/placebo (risk ratio (RR) 1." | 2.66 | Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. ( Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM, 2020) |
| "There was a significant reduction in pathological fractures and severe bone pain in the APD group, and hypercalcaemia was prevented." | 2.66 | Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. ( Beex, LV; Bijvoet, OL; Cleton, FJ; Elte, JW; Harinck, HI; Hermans, J; Kroon, HM; Neijt, JP; van Holten-Verzantvoort, AT; Vermey, P, 1987) |
| " For adverse events (AE), the incidence of headache in cancer patients with zoledronic acid was significantly lower than that with pamidronate disodium (RR = 0." | 2.52 | Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis. ( Du, S; Yang, L, 2015) |
| "Bone metastases are associated with pathologic fractures, spinal cord compression, and bone pain and can require narcotics or palliative radiation for pain relief." | 2.48 | Bone-targeted agents: preventing skeletal complications in prostate cancer. ( Morgans, AK; Smith, MR, 2012) |
| "In metastatic breast cancer the most common metastatic site is bone." | 2.47 | [Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer]. ( Taguchi, T, 2011) |
| "Zoledronic acid has also demonstrated significant long-term benefits in randomized trials in prostate cancer and other solid tumors, whereas other bisphosphonates have failed." | 2.43 | Management of bone metastases in breast cancer. ( Lipton, A, 2005) |
| "Zoledronic acid has also been compared with another active bisphosphonate (i." | 2.43 | Bisphosphonates in breast cancer. ( Coleman, RE, 2005) |
| " The safety profiles among all intravenous bisphosphonates were similar; patients treated with intravenous bisphosphonates reported notably less bone pain but a higher incidence of mild to moderate transient infusion-related adverse events (eg, nausea, vomiting, myalgia, and anorexia) compared with placebo." | 2.43 | Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. ( Gordon, DH, 2005) |
| "Zoledronic acid has also received the broadest regulatory approval of any bisphosphonate and can be used to treat HCM or bone lesions secondary to multiple myeloma and a wide variety of solid tumors, including breast, prostate, and lung cancers." | 2.42 | Safety and convenience of a 15-minute infusion of zoledronic acid. ( Berenson, J; Hirschberg, R, 2004) |
| "Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status." | 2.41 | [Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002) |
| "Zoledronic acid (4 mg) has been compared to placebo in a randomized Phase III trial involving 422 men with hormone-refractory prostate cancer metastatic to bone." | 2.41 | The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. ( Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M, 2002) |
| "Oral etidronate has been found to be ineffective in patients with multiple myeloma and prostate carcinoma bone metastases." | 2.41 | Oral bisphosphonates: A review of clinical use in patients with bone metastases. ( Berenson, J; Hortobagyi, G; Lipton, A; Major, PP, 2000) |
| "Patients with breast cancer associated solely with osseous metastasis may survive for a number of years." | 2.41 | [Therapeutic value of aredia in treatment of breast carcinoma]. ( Diel, IJ, 2000) |
| "Patients with breast cancer associated solely with osseous metastasis may live for a number of years." | 2.41 | Treatment of metastatic bone disease in breast cancer: bisphosphonates. ( Bastert, G; Diel, IJ; Solomayer, EF, 2000) |
| "Pamidronate is a second-generation aminobisphosphonate that is a much more potent inhibitor of osteoclastic activity." | 2.40 | Bisphosphonates and breast carcinoma. ( Lipton, A, 1997) |
| "Experts in the field were approached." | 2.40 | Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. ( Bloomfield, DJ, 1998) |
| "Pamidronate (APD) is a potent inhibitor of bone resorption that is useful in the management of patients with osteolytic bone metastases from breast cancer or multiple myeloma, tumour-induced hypercalcaemia or Paget's disease of bone." | 2.40 | Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. ( Coukell, AJ; Markham, A, 1998) |
| " Review of the published literature suggests that a clinically relevant dose-response relationship exists in the dose range 30-60 mg; most hypercalcemic patients will achieve normocalcemia with a dose of 60 mg pamidronate or more." | 2.39 | Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects? ( Thürlimann, B, 1994) |
| "Haematologic malignancies and solid tumors are often complicated by the bone tissue destruction." | 2.39 | [Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis]. ( Kiełbiński, M, 1994) |
| "The variability of different breast cancers in the susceptibility to metastatic bone disease is poorly understood." | 2.39 | Rationale for the use of bisphosphonates in breast cancer. ( Kanis, JA, 1996) |
| " In conclusion, RT combined with BMA was found to be more effective than BMA alone for the treatment of osteolytic bone metastasis, which thereby improves the prognosis." | 1.56 | Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. ( Kajima, M; Makita, C; Manabe, Y; Matsuo, M; Matsuyama, K; Tanaka, H, 2020) |
| "BACKGROUND Hypercalcemia is a common complication in the intensive care unit (ICU)." | 1.48 | Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report. ( El Madhoun, I; El Zeer, HS; Khatib, M; Mahmoud, S; Mitwally, H, 2018) |
| " This focused update addressed the new data on intervals between dosing and the role of BMAs in control of bone pain." | 1.46 | Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. ( Barlow, WE; Biermann, JS; Bosserman, LD; Clemons, MJ; Dhesy-Thind, SK; Dillmon, MS; Eisen, A; Frank, ES; Jagsi, R; Jimenez, R; Moy, B; Somerfield, MR; Theriault, RL; Van Poznak, C; Vandenberg, TA; Yee, GC, 2017) |
| "The medical records of 534 women with breast cancer who developed bone metastases between 1999 and 2011 were reviewed." | 1.43 | Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. ( Fujimoto, M; Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kinoshita, F; Kodaira, M; Shimizu, C; Takahashi, N; Tamura, K; Tanaka, R; Yamamoto, H; Yonemori, K; Yunokawa, M, 2016) |
| " The repeat dosing of Pam-Doxo-NPs in dogs with naturally occurring OS indicated the therapeutic was well tolerated without hematologic, nonhematologic, and cardiac toxicities." | 1.43 | Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis. ( Borst, LB; Cai, K; Cheng, J; Dobrucki, LW; Fan, TM; Helferich, WG; Kamstock, D; Song, Z; Sternberg, R; Tang, L; Tong, R; Yang, X; Yin, Q, 2016) |
| "Nineteen patients were diagnosed with breast cancer and 18 with prostate cancer." | 1.40 | Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study. ( Angelis, CD; Burke, N; Giotis, A; Goeree, R; Habib, M; Hopkins, RB; Pasetka, M; Xie, F, 2014) |
| "Hypercalcemia is mainly caused by bone resorption due to either secretion of cytokines including parathyroid hormone-related protein (PTHrP) or bone metastases." | 1.38 | Impact of chemotherapy on hypercalcemia in breast and lung cancer patients. ( Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB, 2012) |
| "Repair of pathologic fracture can result in palliation and prolonged survival." | 1.37 | Outcome after repair of a sarcoma-related pathologic fracture in dogs: a Veterinary Society of Surgical Oncology Retrospective Study. ( Bacon, NJ; Bhandal, J; Boston, SE; Bruce, C; Cavanaugh, RP; Culp, WT; Hamilton, MH; Lincoln, JD; Liptak, JM; Scharvogel, S, 2011) |
| "SREs included radiation (79%), pathologic fractures (12%), and hypercalcemia (9%)." | 1.36 | Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. ( Clemons, M; Dranatisaris, G; Myers, J; Simmons, C; Trinkaus, M, 2010) |
| "The patient had a medical history of breast cancer with bone metastasis that was treated by chemotherapy with 45 mg pamidronate in 2 weekly courses for 16 months." | 1.36 | [A case of breast cancer with extensive osteonecrosis of maxilla induced by a bisphosphonate]. ( Inokuchi, S; Koga, C; Koga, M; Kusukawa, J; Tanaka, Y; Yokomizo, Y, 2010) |
| "In total, 55,864 women with breast cancer were included, with 307,467 person-years of follow-up." | 1.35 | Use of intravenous bisphosphonates in older women with breast cancer. ( Duan, Z; Fang, S; Giordano, SH; Goodwin, JS; Hortobagyi, GN; Kuo, YF, 2008) |
| "Majority of patients with prostate cancer develop bone metastases which lead to serious skeletal complications." | 1.35 | [Efficiency of second-generation bisphosphonate in treating patients with prostate cancer and bone metastases]. ( Ali-zade, AM; Kerimov, AKh; Musaev, TN, 2008) |
| "However, for women, metastatic breast cancer still remains the number one cause of cancer death in Europe, and the detection and treatment of micrometastatic disease represent the most important challenge in breast cancer management." | 1.35 | Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? ( Coleman, RE, 2009) |
| "Pamidronate was administered once in a week before PC." | 1.35 | Percutaneous cementoplasty in the palliative, multimodal treatment of primary bone tumors of the distal aspect of the radius in four dogs. ( Böttcher, P; Florian, S; Hierholzer, J; Hildebrandt, G; Krastel, D; Oechtering, G; Vera, G; Westphalen, K, 2009) |
| "Pamidronate was well tolerated and only grade 1 or 2 toxicities were registered." | 1.35 | Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis. ( Mitterer, M; Seeber, A; Spizzo, G, 2009) |
| "We report a renal cell carcinoma case in which multiple lung and bone metastases displayed remarkable remission to BP therapy using 30 mg pamidronate once, 4 mg zoledronate once, and weekly 10 mg incadronate 10 times for 3 months." | 1.35 | Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. ( Fujii, Y; Fukui, I; Kijima, T; Okubo, Y; Suyama, T; Yonese, J, 2008) |
| " Twelve patients who presented with exposed bone associated with bisphosphonates were reviewed to determine the type, dosage and duration of their bisphosphonate therapy, presenting findings, comorbidities and the event that incited the bone exposure." | 1.34 | Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. ( Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E, 2007) |
| "Pamidronate treatment reduced tumor burden as assessed at autopsy by imaging and biomarkers." | 1.33 | Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP. ( Barken, I; Burton, DW; Deftos, LJ; Geller, J; Hastings, RH; Hoffman, RM; Jiang, P; Yang, M, 2005) |
| "Over last 10 years, cases of jaw bone necrosis have been associated with the use of bisphosphonate therapy." | 1.33 | Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report. ( Corradi, D; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P, 2005) |
| "Sixty-two (52." | 1.33 | Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. ( Broumand, V; Fortin, M; Marx, RE; Sawatari, Y, 2005) |
| "The frequency of bone metastases of breast cancer has been reported to be 65-75% of all breast cancer patients, and, in autopsy example at Shikoku Cancer Center, metastasis was recognized to be 74." | 1.33 | [The incidence and management of bone metastasis from breast cancer]. ( Fujiuchi, N; Ookubo, K; Saeki, T; Takeuchi, H, 2006) |
| "Here we report 29 cases of bone necrosis of the jaws in patients treated with pamidronate (Aredia), zoledronate (Zometa) and alendronate: 15 underwent surgical procedures and 14 occurred spontaneously." | 1.33 | Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases. ( Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E, 2006) |
| "Conversely, in Paget's disease and prostate cancer-induced bone metastases, conditions characterized by focal increased bone turnover, alpha L CTX levels were more elevated than those of age-related CTX forms, resulting in increased ratios between native and age-modified CTX." | 1.32 | Investigation of bone disease using isomerized and racemized fragments of type I collagen. ( Body, JJ; Christgau, S; Christiansen, C; Cloos, PA; Delmas, P; Engsig, M; Fledelius, C; Garnero, P, 2003) |
| "Hypocalcemia is a potential adverse effect of these drugs, which is considered infrequent and rarely symptomatic." | 1.32 | Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports. ( Basuyau, JP; Brunelle, P; Champallou, C; Chevrier, A; Chinet, P; Debled, M; Grongnet, MH; Veyret, C, 2003) |
| "Long-term pamidronate treatment of prostate cancer bone metastases does not generally affect the ability to detect bone metastases with Tc99 MDP bone scintigraphy." | 1.32 | Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. ( Higano, CS; King, SH; Ott, SM; Roudier, MP; True, LD; Vessella, RL; Vesselle, H, 2003) |
| "Intravenous drip of pamidronate was given at the dose of 30 - 60 mg per day for 2 - 3 weeks with a total dosage of 90 - 270 (168 +/- 84) mg to 5 patients with Paget's disease of bone, 2 males and 3 females, aged 27 - 74 (61 on average) with the course of disease of 4 - 48 years (24 years on average), all of them having multiple bone lesions, 2 being in grade 4 of pain assessment and bedridden and 3 being in grade 3 with impaired mobility." | 1.32 | [Prospective study of pamidronate disodium in treatment of Paget's disease of bone]. ( Fu, Y; Jiang, Y; Li, M; Meng, XW; Wang, O; Xia, WB; Xing, XP; Zhang, ZL; Zhou, XY, 2003) |
| "This study presents 3 cases of refractory pain from bone metastases due to thyroid, colorectal and hepatocellular carcinoma." | 1.32 | [Bisphosphonate as an adjuvant therapy for the pain of bone metastases, 3 cases]. ( Hattori, S; Kudo, K; Miyakawa, H; Noguchi, T; Okuda, K, 2004) |
| "Giant cell tumor of bone is an aggressive tumor characterized by extensive bone destruction and high recurrence rates." | 1.32 | Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis. ( Blaine, TA; Chang, SS; Doppelt, JD; Jung, KM; Kim, TW; Lee, FY; Suratwala, SJ; Winchester, RJ; Zhang, HZ, 2004) |
| "Zoledronic acid also attenuated mechanical hyperalgesia associated with chronic peripheral neuropathy and inflammation in the rat." | 1.31 | Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. ( Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K, 2002) |
| "Pamidronate was the most popular choice of drug, but a number of respondents chose to use clodronate, often on the basis of cost saving." | 1.31 | Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK. ( Johnson, IS, 2001) |
| "Pamidronate was injected intravenously at 60 mg over 3 h." | 1.30 | Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2. ( Barni, S; Brivio, F; Cazzaniga, M; Fumagalli, L; Lissoni, P; Perego, MS; Tancini, G, 1997) |
| "Tumor-induced osteolysis is essentially mediated by the osteoclasts whose number and activity appear to be stimulated under the influence of tumor secretory products." | 1.30 | [Bone metastases: pathogenesis and treatment with diphosphonates]. ( Body, JJ, 1997) |
| "Pamidronate is an effective drug used not only in patients with tumor-associated hypercalcemia, but also in normocalcemic patients with metastatic bone disease to relieve pains." | 1.30 | Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate. ( Alakavuklar, M; Biberoglu, S; Cömlekçi, A; Hekimsoy, Z; Okan, I; Pişkin, O; Sekeroglu, B, 1998) |
| "Nocturnal infusion of 5-fluorouracil (5-FU) combined with pamidronate was performed in a 62-year-old male gastric cancer patient with multiple bone metastasis." | 1.30 | [A case of gastric cancer with multiple bone metastasis treated by nocturnal 5-fluorouracil infusion combined with pamidronate]. ( Fukano, S; Furuya, Y; Kinugasa, T; Kohno, N; Maekawa, Y; Sekimoto, K; Toyokawa, A, 1998) |
| "The baseline levels of bone resorption markers were used to predict the probability of non-progressive bone disease or reduction in pain intensity during bisphosphonate therapy." | 1.30 | Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. ( Engler, H; Koeberle, D; Riesen, WF; Senn, HJ; Thuerlimann, B, 1998) |
| "APD is itself a bone cancer pain palliation agent and this work was therefore driven by the idea that the energetic beta-particle emitter, 166Ho, coupled with APD could afford a highly effective radiopharmaceutical in the treatment of bone cancer." | 1.30 | Metal-ion speciation in blood plasma incorporating the bisphosphonate, 1-hydroxy-4-aminopropilydenediphosphonate (APD), in therapeutic radiopharmaceuticals. ( Cukrowski, I; Jackson, GE; Jarvis, NV; Louw, WK; Mouton, CJ; Zeevaart, JR, 1999) |
| "To validate our hypothesis that a bisphosphonate (BP) having a nitrogen-containing heterocyclic ring on the side chain, and with no hydroxyl on the geminal carbon would possess increased activity, and better oral bioavailability due to enhanced solubility of its calcium complexes/salts and weaker Ca chelating properties." | 1.30 | Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. ( Alferiev, IS; Breuer, E; Cohen, H; Ezra, A; Golomb, G; Hägele, G; Hoffman, A; Mönkkönen, J; Ornoy, A; Patlas, N; Pinto, T; Sagi, H; Seibel, MJ; Solomon, V; Stepensky, D, 1999) |
| " In the present study we have evaluated the therapeutic efficacy of pamidronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid) combined with mitomycin C (MMC) on bone metastasis of breast cancer using an animal model." | 1.29 | Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model. ( Enomoto, K; Ikeda, T; Ishii, S; Kitajima, M; Tamura, H; Wada, N, 1996) |
| "Pamidronate is a second-generation bisphosphonate used in the treatment of tumor-induced hypercalcemia and in the management of bone metastases from breast cancer, myeloma, or prostate cancer." | 1.28 | Pharmacokinetics of pamidronate in patients with bone metastases. ( Bauer, J; Burckhardt, P; Flesch, G; Ford, JM; Hauffe, S; Hess, U; Leyvraz, S, 1992) |
| " The author discusses the administration, dosage and side effects, and results of current studies." | 1.28 | Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy. ( Coleman, RE, 1991) |
| "No other systemic therapy for breast cancer was prescribed." | 1.27 | Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD). ( Coleman, RE; Miles, M; Rubens, RD; Scrivener, W; Woll, PJ, 1988) |
| " No significant increase in the median survival time of tumor-bearing animals was achieved at the two dosage schemes tested, i." | 1.27 | Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma. ( Schmähl, D; Wingen, F, 1985) |
| "The effects of the treatment of multiple myeloma (MM) with APD-bisphosphonate on bone destruction, the dissemination pattern of the MM, and toxicity for normal and malignant cells were investigated in an animal model, the 5T2 MM." | 1.27 | Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma. ( Bijvoet, OL; Brondijk, RJ; Croese, JW; Haaijman, JJ; Kazil, M; Radl, J; Reitsma, PH; van den Enden-Vieveen, MH; Zurcher, C, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 19 (5.34) | 18.7374 |
| 1990's | 111 (31.18) | 18.2507 |
| 2000's | 161 (45.22) | 29.6817 |
| 2010's | 58 (16.29) | 24.3611 |
| 2020's | 7 (1.97) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 2 |
| Tang, Z | 1 |
| Meng, R | 1 |
| He, L | 1 |
| Fusco, V | 1 |
| Campisi, G | 1 |
| Bedogni, A | 1 |
| Shen, CY | 1 |
| Au, PC | 1 |
| Baek, YH | 1 |
| Cheung, CL | 1 |
| Chung, WP | 1 |
| Kim, JH | 1 |
| Kleinman, NJ | 1 |
| Lam, TC | 1 |
| Liao, TC | 1 |
| Lin, TC | 1 |
| Shin, JY | 1 |
| Sing, CW | 1 |
| Wong, ICK | 1 |
| Lai, EC | 1 |
| Nakamura, M | 1 |
| Ueda, K | 1 |
| Yamamoto, Y | 1 |
| Aoki, K | 1 |
| Zhang, M | 1 |
| Saito, N | 1 |
| Yudasaka, M | 1 |
| Tanaka, H | 1 |
| Makita, C | 1 |
| Manabe, Y | 1 |
| Kajima, M | 1 |
| Matsuyama, K | 2 |
| Matsuo, M | 1 |
| Jakob, T | 1 |
| Tesfamariam, YM | 1 |
| Macherey, S | 1 |
| Kuhr, K | 1 |
| Adams, A | 1 |
| Monsef, I | 1 |
| Heidenreich, A | 1 |
| Skoetz, N | 1 |
| Jara, MA | 1 |
| Varghese, J | 1 |
| Hu, MI | 1 |
| Van Poznak, C | 2 |
| Somerfield, MR | 2 |
| Moy, B | 2 |
| Barlow, WE | 2 |
| Biermann, JS | 2 |
| Bosserman, LD | 2 |
| Clemons, MJ | 2 |
| Dhesy-Thind, SK | 1 |
| Dillmon, MS | 1 |
| Eisen, A | 1 |
| Frank, ES | 1 |
| Jagsi, R | 1 |
| Jimenez, R | 1 |
| Theriault, RL | 6 |
| Vandenberg, TA | 1 |
| Yee, GC | 2 |
| Mahmoud, S | 1 |
| Mitwally, H | 1 |
| El Zeer, HS | 1 |
| El Madhoun, I | 1 |
| Khatib, M | 1 |
| Matuoka, JY | 1 |
| Kahn, JG | 1 |
| Secoli, SR | 1 |
| Kim, S | 1 |
| Kozicki, AR | 1 |
| Robat, C | 1 |
| Chun, R | 1 |
| Kurzman, ID | 1 |
| De Ponte, FS | 2 |
| Favaloro, A | 1 |
| Siniscalchi, EN | 1 |
| Centofanti, A | 1 |
| Runci, M | 1 |
| Cutroneo, G | 1 |
| Catalfamo, L | 1 |
| Cornelis, F | 1 |
| Truchetet, ME | 1 |
| Amoretti, N | 1 |
| Verdier, D | 1 |
| Fournier, C | 1 |
| Pillet, O | 1 |
| Gille, O | 1 |
| Hauger, O | 1 |
| Abdelaziz, DM | 1 |
| Stone, LS | 1 |
| Komarova, SV | 1 |
| Oster, G | 1 |
| Lamerato, L | 1 |
| Glass, AG | 1 |
| Richert-Boe, KE | 1 |
| Lopez, A | 1 |
| Chung, K | 1 |
| Richhariya, A | 1 |
| Dodge, T | 1 |
| Wolff, GG | 1 |
| Balakumaran, A | 1 |
| Edelsberg, J | 1 |
| McKay, RR | 1 |
| Lin, X | 1 |
| Perkins, JJ | 1 |
| Heng, DY | 1 |
| Simantov, R | 1 |
| Choueiri, TK | 1 |
| Addison, CL | 1 |
| Bouganim, N | 2 |
| Hilton, J | 1 |
| Vandermeer, L | 2 |
| Dent, S | 2 |
| Amir, E | 2 |
| Hopkins, S | 1 |
| Kuchuk, I | 2 |
| Segal, R | 1 |
| Song, X | 2 |
| Gertler, S | 2 |
| Mazzarello, S | 2 |
| Dranitsaris, G | 6 |
| Ooi, D | 1 |
| Pond, G | 1 |
| Clemons, M | 7 |
| Xie, F | 2 |
| Hopkins, RB | 1 |
| Burke, N | 2 |
| Habib, M | 1 |
| Angelis, CD | 1 |
| Pasetka, M | 1 |
| Giotis, A | 1 |
| Goeree, R | 2 |
| Papamerkouriou, YM | 1 |
| Kenanidis, E | 1 |
| Gamie, Z | 1 |
| Papavasiliou, K | 1 |
| Kostakos, T | 1 |
| Potoupnis, M | 1 |
| Sarris, I | 1 |
| Tsiridis, E | 1 |
| Kyrkos, J | 1 |
| Criscitiello, C | 1 |
| Viale, G | 1 |
| Gelao, L | 1 |
| Esposito, A | 1 |
| De Laurentiis, M | 1 |
| De Placido, S | 1 |
| Santangelo, M | 1 |
| Goldhirsch, A | 2 |
| Curigliano, G | 1 |
| Wang, Z | 1 |
| Qiao, D | 1 |
| Lu, Y | 2 |
| Curtis, D | 1 |
| Wen, X | 1 |
| Yao, Y | 1 |
| Zhao, H | 1 |
| Wright, JD | 1 |
| Tergas, AI | 1 |
| Ananth, CV | 1 |
| Burke, WM | 1 |
| Hou, JY | 1 |
| Chen, L | 1 |
| Neugut, AI | 1 |
| Richards, CA | 1 |
| Hershman, DL | 1 |
| Yang, L | 1 |
| Du, S | 1 |
| Huang, CY | 1 |
| Wang, L | 1 |
| Feng, CJ | 1 |
| Yu, P | 1 |
| Cai, XH | 1 |
| Yao, WX | 1 |
| Xu, Y | 1 |
| Liu, XK | 1 |
| Zhu, WJ | 1 |
| Zhou, J | 1 |
| Wang, YS | 1 |
| Jacobs, C | 1 |
| Smith, S | 1 |
| Verma, S | 3 |
| Simos, S | 1 |
| Cella, D | 1 |
| Rayson, D | 1 |
| Tanaka, R | 1 |
| Yonemori, K | 1 |
| Hirakawa, A | 1 |
| Kinoshita, F | 1 |
| Takahashi, N | 1 |
| Hashimoto, J | 1 |
| Kodaira, M | 1 |
| Yamamoto, H | 1 |
| Yunokawa, M | 1 |
| Shimizu, C | 1 |
| Fujimoto, M | 1 |
| Fujiwara, Y | 1 |
| Tamura, K | 1 |
| Marker, BA | 1 |
| Barber, LG | 1 |
| Clifford, CA | 1 |
| Correa, SS | 1 |
| Thalhofer, PL | 1 |
| LaDue, TA | 1 |
| Mullin, CM | 1 |
| Sauerbrey, ML | 1 |
| Wood, CC | 1 |
| Veszelyné Kotán, E | 2 |
| Mészaros, Á | 2 |
| Pagano, C | 1 |
| Boudreaux, B | 1 |
| Shiomitsu, K | 1 |
| Yin, Q | 1 |
| Tang, L | 1 |
| Cai, K | 1 |
| Tong, R | 1 |
| Sternberg, R | 1 |
| Yang, X | 1 |
| Dobrucki, LW | 1 |
| Borst, LB | 1 |
| Kamstock, D | 1 |
| Song, Z | 1 |
| Helferich, WG | 1 |
| Cheng, J | 1 |
| Fan, TM | 1 |
| Roderick, MR | 1 |
| Shah, R | 1 |
| Rogers, V | 1 |
| Finn, A | 1 |
| Ramanan, AV | 1 |
| Giordano, SH | 1 |
| Fang, S | 1 |
| Duan, Z | 1 |
| Kuo, YF | 1 |
| Hortobagyi, GN | 4 |
| Goodwin, JS | 1 |
| Aarabi, S | 1 |
| Draper, L | 1 |
| Grayson, B | 1 |
| Gurtner, GC | 1 |
| La Verde, N | 1 |
| Bareggi, C | 1 |
| Garassino, M | 1 |
| Borgonovo, K | 1 |
| Sburlati, P | 1 |
| Pedretti, D | 1 |
| Bianchi, C | 1 |
| Perrone, S | 1 |
| Mihali, D | 1 |
| Cobelli, S | 1 |
| Mantica, C | 1 |
| Rizzo, A | 1 |
| Farina, G | 1 |
| Dong, M | 1 |
| Feng, FY | 1 |
| Zhang, Y | 2 |
| Xie, GR | 1 |
| Wang, YJ | 1 |
| Liu, JW | 1 |
| Song, ST | 1 |
| Zhou, QH | 1 |
| Ren, J | 2 |
| Jiao, SC | 1 |
| Li, J | 1 |
| Wang, XW | 1 |
| Chen, Q | 1 |
| Wang, ZH | 1 |
| Xu, N | 1 |
| Feng, JF | 1 |
| Vassiliou, V | 1 |
| Kardamakis, D | 1 |
| Kalogeropoulou, C | 1 |
| Dasanu, CA | 1 |
| Alexandrescu, DT | 1 |
| Musaev, TN | 1 |
| Kerimov, AKh | 1 |
| Ali-zade, AM | 1 |
| Osanai, T | 2 |
| Tsuchiya, T | 2 |
| Sugawara, M | 1 |
| Trinkaus, M | 1 |
| Simmons, C | 1 |
| Myers, J | 1 |
| Dranatisaris, G | 1 |
| Coleman, RE | 28 |
| Machado, M | 1 |
| Cruz, LS | 1 |
| Tannus, G | 1 |
| Fonseca, M | 1 |
| Nagahama, M | 1 |
| Sica, DA | 1 |
| Major, PP | 3 |
| Cook, RJ | 4 |
| Lipton, A | 23 |
| Smith, MR | 4 |
| Terpos, E | 4 |
| Böttcher, P | 1 |
| Krastel, D | 1 |
| Hierholzer, J | 1 |
| Westphalen, K | 1 |
| Florian, S | 1 |
| Hildebrandt, G | 1 |
| Vera, G | 1 |
| Oechtering, G | 1 |
| Crawford, BS | 1 |
| McNulty, RM | 1 |
| Kraut, EH | 1 |
| Turowski, RC | 1 |
| Spizzo, G | 1 |
| Seeber, A | 1 |
| Mitterer, M | 1 |
| Otto, S | 1 |
| Schuler, K | 1 |
| Ihrler, S | 1 |
| Ehrenfeld, M | 1 |
| Mast, G | 1 |
| Göllner, M | 1 |
| Holst, S | 1 |
| Fenner, M | 1 |
| Schmitt, J | 1 |
| Tanaka, Y | 1 |
| Koga, M | 1 |
| Yokomizo, Y | 1 |
| Inokuchi, S | 1 |
| Koga, C | 1 |
| Kusukawa, J | 1 |
| McMahon, MB | 1 |
| Bear, MD | 1 |
| Kulp, SK | 1 |
| Pennell, ML | 1 |
| London, CA | 1 |
| Heras, P | 1 |
| Hatzopoulos, A | 1 |
| Heras, V | 1 |
| Kritikos, N | 1 |
| Karagiannis, S | 1 |
| Kritikos, K | 1 |
| Weinstein, E | 1 |
| Arnold, RM | 1 |
| Joerger, M | 1 |
| Templeton, A | 1 |
| Köberle, D | 1 |
| Engler, H | 2 |
| Riesen, WF | 2 |
| Thürlimann, B | 3 |
| ten Dam, MA | 1 |
| Hilbrands, LB | 1 |
| Wetzels, JF | 1 |
| Deuber, HJ | 1 |
| Theiss, F | 1 |
| Lau, CP | 1 |
| Huang, L | 2 |
| Tsui, SK | 1 |
| Ng, PK | 1 |
| Leung, PY | 1 |
| Kumta, SM | 2 |
| Aapro, M | 1 |
| Saad, F | 3 |
| Costa, L | 3 |
| Price, AP | 1 |
| Abramson, SJ | 2 |
| Hwang, S | 1 |
| Chou, A | 1 |
| Bartolotta, R | 1 |
| Meyers, P | 1 |
| Katz, DS | 1 |
| Rajkumar, SV | 1 |
| Van Poznak, CH | 1 |
| Temin, S | 1 |
| Janjan, NA | 1 |
| Geoghegan, C | 1 |
| Hillner, BE | 2 |
| Zuckerman, DS | 1 |
| Von Roenn, JH | 1 |
| Dimopoulos, MA | 2 |
| Berenson, J | 3 |
| Taguchi, T | 1 |
| Yoshizawa, H | 1 |
| Akimoto, T | 1 |
| Nishino, K | 1 |
| Inoue, M | 1 |
| Ito, C | 1 |
| Takeda, S | 1 |
| Kotoda, A | 1 |
| Tamba, K | 1 |
| Yumura, W | 1 |
| Muto, S | 1 |
| Ueda, Y | 1 |
| Kusano, E | 1 |
| Boston, SE | 2 |
| Bacon, NJ | 1 |
| Culp, WT | 1 |
| Bhandal, J | 1 |
| Bruce, C | 1 |
| Cavanaugh, RP | 1 |
| Hamilton, MH | 1 |
| Lincoln, JD | 1 |
| Liptak, JM | 1 |
| Scharvogel, S | 1 |
| Meyers, PA | 1 |
| Healey, JH | 1 |
| Chou, AJ | 1 |
| Wexler, LH | 1 |
| Merola, PR | 1 |
| Morris, CD | 1 |
| Laquaglia, MP | 1 |
| Kellick, MG | 1 |
| Gorlick, R | 1 |
| Nakayama, H | 1 |
| Kawase, T | 1 |
| Okuda, K | 2 |
| Wolff, LF | 1 |
| Yoshie, H | 1 |
| Niikura, N | 1 |
| Liu, J | 1 |
| Hayashi, N | 1 |
| Palla, SL | 1 |
| Tokuda, Y | 1 |
| Ueno, NT | 1 |
| Hopkins, R | 1 |
| Tarride, JE | 1 |
| Hirschberg, R | 2 |
| Freedman, O | 1 |
| Carlsson, L | 1 |
| Tomlinson, G | 1 |
| Laupacis, A | 1 |
| Tannock, IF | 1 |
| Brown, JE | 1 |
| Morgans, AK | 1 |
| Hassan, BA | 1 |
| Yusoff, ZB | 1 |
| Hassali, MA | 1 |
| Othman, SB | 1 |
| Weiderpass, E | 1 |
| Oblak, ML | 1 |
| Higginson, G | 1 |
| Patten, SG | 1 |
| Monteith, GJ | 1 |
| Woods, JP | 1 |
| Murphy, L | 1 |
| McCarthy, J | 1 |
| McCrate, F | 1 |
| Laing, K | 1 |
| Powell, E | 1 |
| Seal, M | 1 |
| Edwards, S | 1 |
| Nagykálnai, T | 1 |
| Landherr, L | 1 |
| Zatkóné, GP | 1 |
| Gyuricska, A | 1 |
| Cloos, PA | 1 |
| Fledelius, C | 1 |
| Christgau, S | 1 |
| Christiansen, C | 1 |
| Engsig, M | 1 |
| Delmas, P | 1 |
| Body, JJ | 16 |
| Garnero, P | 2 |
| Pistevou-Gombaki, K | 2 |
| Eleftheriadis, N | 1 |
| Sofroniadis, I | 1 |
| Makris, P | 1 |
| Kouloulias, V | 2 |
| Small, E | 1 |
| Gleason, D | 1 |
| Gordon, D | 2 |
| Smith, M | 1 |
| Rosen, L | 1 |
| Kowalski, MO | 2 |
| Reitsma, D | 1 |
| Seaman, J | 5 |
| Petcu, EB | 1 |
| Schug, SA | 1 |
| Smith, H | 1 |
| Walker, K | 1 |
| Medhurst, SJ | 1 |
| Kidd, BL | 1 |
| Glatt, M | 1 |
| Bowes, M | 1 |
| Patel, S | 1 |
| McNair, K | 1 |
| Kesingland, A | 1 |
| Green, J | 1 |
| Chan, O | 1 |
| Fox, AJ | 1 |
| Urban, LA | 1 |
| Greipp, P | 1 |
| Facon, T | 3 |
| Geurs, F | 2 |
| Fermand, JP | 1 |
| Harousseau, JL | 1 |
| Mariette, X | 1 |
| Williams, CD | 1 |
| Nakanishi, A | 1 |
| Holloway, D | 2 |
| Martin, SW | 1 |
| Dunstan, CR | 1 |
| Bekker, PJ | 2 |
| Cook, R | 1 |
| Champallou, C | 1 |
| Basuyau, JP | 1 |
| Veyret, C | 1 |
| Chinet, P | 1 |
| Debled, M | 1 |
| Chevrier, A | 1 |
| Grongnet, MH | 1 |
| Brunelle, P | 1 |
| El-Abdaimi, K | 1 |
| Ste-Marie, LG | 1 |
| Papavasiliou, V | 1 |
| Dion, N | 1 |
| Cardinal, PE | 1 |
| Huang, D | 1 |
| Kremer, R | 1 |
| Roudier, MP | 1 |
| Vesselle, H | 1 |
| True, LD | 1 |
| Higano, CS | 1 |
| Ott, SM | 1 |
| King, SH | 1 |
| Vessella, RL | 1 |
| Kouloulias, EV | 1 |
| Kouvaris, RJ | 1 |
| Antypas, C | 2 |
| Mystakidou, K | 2 |
| Matsopoulos, G | 2 |
| Uzunoglu, CN | 1 |
| Moulopoulos, A | 2 |
| Vlahos, JL | 1 |
| de la Fuente, J | 1 |
| Szydlo, R | 1 |
| Hatjiharissi, E | 1 |
| Viniou, N | 1 |
| Meletis, J | 1 |
| Yataganas, X | 1 |
| Goldman, JM | 1 |
| Rahemtulla, A | 1 |
| Kouvaris, J | 1 |
| Dardoufas, C | 1 |
| Bottomley, A | 1 |
| Varela, M | 1 |
| Uzunoglu, N | 1 |
| Metafa, A | 1 |
| Sandilos, P | 1 |
| Vlahos, L | 1 |
| Subramanian, PS | 1 |
| Kerrison, JB | 1 |
| Calvert, PC | 1 |
| Miller, NR | 1 |
| Rosen, LS | 3 |
| Kaminski, M | 2 |
| Howell, A | 8 |
| Belch, A | 1 |
| Mackey, J | 1 |
| Apffelstaedt, J | 1 |
| Hussein, MA | 1 |
| Reitsma, DJ | 2 |
| Chen, BL | 2 |
| Seaman, JJ | 5 |
| Enright, K | 1 |
| Chow, E | 1 |
| Small, EJ | 1 |
| Petrone, S | 1 |
| Kelly, WK | 1 |
| Steineck, G | 1 |
| Tarassoff, P | 1 |
| Csermak, K | 1 |
| Zhang, ZL | 1 |
| Meng, XW | 1 |
| Xing, XP | 1 |
| Wang, O | 1 |
| Xia, WB | 1 |
| Li, M | 1 |
| Jiang, Y | 1 |
| Fu, Y | 1 |
| Zhou, XY | 1 |
| Gordon, DH | 2 |
| Dugan, W | 1 |
| Major, P | 2 |
| Eisenberg, PD | 1 |
| Provencher, L | 1 |
| Simeone, J | 2 |
| Berenson, JR | 2 |
| Weinfurt, KP | 1 |
| Castel, LD | 1 |
| Li, Y | 1 |
| Timbie, JW | 2 |
| Glendenning, GA | 2 |
| Schulman, KA | 3 |
| Chen, BE | 1 |
| Haverbeke, G | 1 |
| Pertile, G | 1 |
| Claes, C | 1 |
| Zeyen, T | 1 |
| Senkus-Konefka, E | 1 |
| Krasińska, L | 1 |
| Pikiel, J | 1 |
| Krasińska, W | 1 |
| Nowaczyk, M | 1 |
| Jassem, J | 1 |
| Hattori, S | 1 |
| Miyakawa, H | 1 |
| Kudo, K | 1 |
| Noguchi, T | 1 |
| Cheng, YY | 1 |
| Lee, KM | 1 |
| Xu, JK | 1 |
| Zheng, MH | 1 |
| Chern, B | 1 |
| Joseph, D | 1 |
| Joshua, D | 1 |
| Pittman, K | 1 |
| Richardson, G | 1 |
| Schou, M | 1 |
| Lowe, S | 1 |
| Copeman, M | 1 |
| De Abreu Lourenco, R | 1 |
| Lynch, K | 1 |
| Altundag, O | 1 |
| Altundag, K | 1 |
| Montemurro, F | 1 |
| Russo, F | 1 |
| Martincich, L | 1 |
| Cirillo, S | 1 |
| Gatti, M | 1 |
| Aglietta, M | 1 |
| Regge, D | 1 |
| Rai, Y | 1 |
| Sagara, Y | 2 |
| Takahama, T | 1 |
| Ando, M | 1 |
| Kouloulias, VE | 2 |
| Kouvaris, JR | 2 |
| Varela, MN | 1 |
| Kokakis, J | 1 |
| Balafouta, M | 1 |
| Gennatas, C | 1 |
| Vlahos, LJ | 2 |
| Romanus, D | 1 |
| Iscoe, N | 1 |
| Deangelis, C | 1 |
| Shear, N | 1 |
| Einarson, TR | 1 |
| Chang, SS | 1 |
| Suratwala, SJ | 1 |
| Jung, KM | 1 |
| Doppelt, JD | 1 |
| Zhang, HZ | 1 |
| Blaine, TA | 1 |
| Kim, TW | 1 |
| Winchester, RJ | 1 |
| Lee, FY | 1 |
| Burton, DW | 2 |
| Geller, J | 2 |
| Yang, M | 2 |
| Jiang, P | 1 |
| Barken, I | 1 |
| Hastings, RH | 2 |
| Hoffman, RM | 2 |
| Deftos, LJ | 2 |
| Conte, P | 1 |
| Coleman, R | 2 |
| Tralongo, P | 1 |
| Repetto, L | 1 |
| Di Mari, A | 1 |
| Mauceri, G | 1 |
| Bollina, R | 1 |
| Ferrau', F | 1 |
| Conti, G | 1 |
| Wada, N | 2 |
| Ishii, S | 2 |
| Ikeda, T | 2 |
| Kitajima, M | 2 |
| Wang, DJ | 1 |
| Liu, HQ | 1 |
| Chen, YL | 1 |
| Zhan, QY | 1 |
| Cai, Y | 1 |
| Liu, MZ | 1 |
| Tanvetyanon, T | 1 |
| Reed, SD | 1 |
| Radeva, JI | 1 |
| Harvey, HA | 2 |
| Saba, N | 1 |
| Khuri, F | 1 |
| Gralow, J | 1 |
| Balla, J | 1 |
| Lugassy, G | 1 |
| De Cock, E | 2 |
| Hutton, J | 2 |
| Canney, P | 2 |
| Barrett-Lee, P | 3 |
| Neary, MP | 2 |
| Lewis, G | 2 |
| Liang, JG | 1 |
| Jiang, NY | 1 |
| DU, JQ | 1 |
| Lu, XP | 1 |
| Liu, XG | 1 |
| Chen, SX | 1 |
| Jimenez-Soriano, Y | 1 |
| Bagan, JV | 1 |
| Liauw, W | 1 |
| Segelov, E | 1 |
| Lih, A | 1 |
| Dunleavy, R | 1 |
| Links, M | 1 |
| Ward, R | 1 |
| Cremers, SC | 1 |
| Papapoulos, SE | 5 |
| Gelderblom, H | 1 |
| Seynaeve, C | 1 |
| den Hartigh, J | 1 |
| Vermeij, P | 1 |
| van der Rijt, CC | 1 |
| van Zuylen, L | 1 |
| Ogino, T | 1 |
| Nakahara, K | 1 |
| Merigo, E | 2 |
| Manfredi, M | 2 |
| Meleti, M | 2 |
| Corradi, D | 2 |
| Vescovi, P | 2 |
| Marx, RE | 1 |
| Sawatari, Y | 1 |
| Fortin, M | 1 |
| Broumand, V | 1 |
| Bamias, A | 1 |
| Kastritis, E | 1 |
| Bamia, C | 1 |
| Moulopoulos, LA | 1 |
| Melakopoulos, I | 1 |
| Bozas, G | 1 |
| Koutsoukou, V | 1 |
| Gika, D | 1 |
| Anagnostopoulos, A | 1 |
| Papadimitriou, C | 1 |
| Zhang, G | 1 |
| Cai, W | 1 |
| Zhou, YF | 1 |
| Li, PW | 1 |
| Gao, YJ | 1 |
| Wang, SJ | 1 |
| Mao, GG | 1 |
| Liu, B | 1 |
| Fan, M | 1 |
| Peterson, MC | 1 |
| Hillegonds, DJ | 1 |
| Dimitrakopoulos, I | 1 |
| Magopoulos, C | 1 |
| Karakasis, D | 1 |
| Sauter, M | 1 |
| Jülg, B | 1 |
| Porubsky, S | 1 |
| Cohen, C | 1 |
| Fischereder, M | 1 |
| Sitter, T | 1 |
| Schlondorff, D | 1 |
| Gröne, HJ | 1 |
| Migliorati, CA | 1 |
| Siegel, MA | 1 |
| Elting, LS | 1 |
| Saeki, T | 1 |
| Ookubo, K | 1 |
| Takeuchi, H | 1 |
| Fujiuchi, N | 1 |
| Barrick, M | 1 |
| Aogi, K | 1 |
| Okita, A | 1 |
| Taira, N | 1 |
| Ohsumi, S | 1 |
| Takashima, S | 1 |
| Ooi, WS | 1 |
| Yogendran, G | 1 |
| Sukovic, T | 1 |
| Wong, BY | 1 |
| Pritchard, KI | 1 |
| Trudeau, M | 1 |
| Cole, DE | 2 |
| Culbert, EC | 1 |
| Schfirin, BS | 1 |
| Nastro, E | 1 |
| Musolino, C | 1 |
| Allegra, A | 1 |
| Oteri, G | 1 |
| Cicciù, M | 1 |
| Alonci, A | 1 |
| Quartarone, E | 1 |
| Alati, C | 1 |
| Guidotti, R | 1 |
| Ripasarti, A | 1 |
| Zanzucchi, E | 1 |
| D'Aleo, P | 1 |
| Corcione, L | 1 |
| Sesenna, E | 1 |
| Ferrari, S | 1 |
| Poli, T | 1 |
| Bonaninil, M | 1 |
| Sherer, JT | 1 |
| Adamus, AT | 1 |
| Ooi, W | 1 |
| Martinetti, A | 1 |
| Ripamonti, C | 3 |
| Miceli, R | 1 |
| Seregni, E | 1 |
| Mariani, L | 1 |
| De Conno, F | 3 |
| Bajetta, E | 2 |
| Bombardieri, E | 1 |
| Kawashima, H | 1 |
| Tanaka, T | 1 |
| Kuratsukuri, K | 1 |
| Uchida, J | 1 |
| Sugimura, K | 1 |
| Tamada, S | 1 |
| Nishisaka, N | 1 |
| Kumata, K | 1 |
| Iwai, Y | 1 |
| Ikemoto, S | 1 |
| Ezaki, K | 1 |
| Nakatani, T | 1 |
| Bloomfield, D | 1 |
| Dougherty, L | 1 |
| Harries, M | 1 |
| Laing, R | 1 |
| Patel, H | 1 |
| Walker, M | 1 |
| Sanna, G | 1 |
| Preda, L | 1 |
| Bruschini, R | 1 |
| Cossu Rocca, M | 1 |
| Verri, E | 1 |
| Bellomi, M | 1 |
| Nole, F | 2 |
| Vieillard, MH | 1 |
| Maes, JM | 1 |
| Penel, G | 1 |
| Magro, L | 1 |
| Bonneterre, J | 2 |
| Cortet, B | 1 |
| George, R | 1 |
| Hephzibah, J | 1 |
| John, S | 1 |
| Yamada, K | 4 |
| Kohno, N | 4 |
| McKeage, K | 1 |
| Plosker, GL | 1 |
| Schivazappa, C | 1 |
| Berto, P | 1 |
| Baldini, E | 1 |
| Barni, S | 2 |
| Dauria, G | 1 |
| Cortesi, E | 1 |
| Kristensen, B | 1 |
| Ejlertsen, B | 1 |
| Mouridsen, HT | 1 |
| Jensen, MB | 1 |
| Andersen, J | 1 |
| Bjerregaard, B | 1 |
| Cold, S | 1 |
| Edlund, P | 1 |
| Ewertz, M | 1 |
| Kamby, C | 1 |
| Lindman, H | 1 |
| Nordenskjöld, B | 1 |
| Bergh, J | 1 |
| Kijima, T | 1 |
| Fujii, Y | 1 |
| Suyama, T | 1 |
| Okubo, Y | 1 |
| Yonese, J | 1 |
| Fukui, I | 1 |
| Tubiana-Hulin, M | 3 |
| de Vernejoul, MC | 1 |
| Brière, M | 1 |
| Miravet, L | 1 |
| Clavel, B | 1 |
| Delmas, PD | 7 |
| Meunier, PJ | 1 |
| Glover, D | 2 |
| Keller, A | 1 |
| Miller, AA | 1 |
| Browning, S | 1 |
| Fram, RJ | 1 |
| George, S | 1 |
| Zelenakas, K | 2 |
| Macerata, RS | 1 |
| Harvey, H | 2 |
| Grabelsky, S | 1 |
| Macerata, R | 1 |
| Tyrrell, CJ | 1 |
| Purohit, OP | 6 |
| Radstone, CR | 2 |
| Anthony, C | 2 |
| Kanis, JA | 5 |
| Macro, M | 1 |
| Bouvard, G | 1 |
| Le Gangneux, E | 1 |
| Colin, T | 1 |
| Loyau, G | 1 |
| van Holten-Verzantvoort, AT | 5 |
| Kroon, HM | 2 |
| Bijvoet, OL | 5 |
| Cleton, FJ | 4 |
| Beex, LV | 3 |
| Blijham, G | 2 |
| Hermans, J | 4 |
| Neijt, JP | 2 |
| Sleeboom, HP | 2 |
| Conte, PF | 2 |
| Giannessi, PG | 1 |
| Latreille, J | 2 |
| Mauriac, L | 3 |
| Koliren, L | 1 |
| Calabresi, F | 2 |
| Ford, JM | 4 |
| Walls, J | 1 |
| Ratcliffe, WA | 1 |
| Bundred, NJ | 1 |
| Kiełbiński, M | 1 |
| Dumon, JC | 3 |
| Owen, J | 1 |
| Gurney, H | 2 |
| Grill, V | 1 |
| Martin, TJ | 2 |
| Colleoni, M | 1 |
| Bochicchio, AM | 1 |
| Grimaux, M | 1 |
| Seguin, P | 1 |
| Morant, R | 1 |
| Jungi, WF | 1 |
| Radziwill, A | 1 |
| Clarke, NW | 2 |
| McClure, J | 2 |
| George, NJ | 2 |
| Mundy, GR | 2 |
| Kostenuik, PJ | 1 |
| Orr, FW | 1 |
| Suyama, K | 1 |
| Singh, G | 1 |
| Lichinitser, MR | 1 |
| Vyshinskaia, GV | 1 |
| Kupchan, DZ | 1 |
| Liubimova, NV | 1 |
| Moreira, C | 1 |
| da Costa, EB | 1 |
| Tyrrell, CT | 1 |
| Bruning, PF | 1 |
| May-Levin, F | 1 |
| Rose, C | 2 |
| Soukop, M | 1 |
| Nesković-Konstantinović, Z | 1 |
| Mitrović, L | 2 |
| Petrović, J | 1 |
| Stamatović, L | 1 |
| Ristović, Z | 1 |
| Piccart, M | 2 |
| Ford, J | 5 |
| Vinholes, J | 3 |
| Guo, CY | 2 |
| Eastell, R | 3 |
| Cascinu, S | 2 |
| Casadei, V | 1 |
| Del Ferro, E | 2 |
| Alessandroni, P | 2 |
| Catalano, G | 2 |
| van Eck-Smit, BC | 1 |
| Santos, R | 1 |
| Campos, D | 1 |
| Francini, G | 1 |
| Paterson, AH | 2 |
| Powles, TJ | 1 |
| McCloskey, E | 1 |
| Hanson, J | 1 |
| Ashley, S | 1 |
| Tamura, H | 1 |
| Enomoto, K | 1 |
| Hiraga, T | 1 |
| Takada, M | 1 |
| Nakajima, T | 1 |
| Ozawa, H | 1 |
| Possinger, K | 2 |
| Flath, B | 1 |
| Akrivakis, K | 1 |
| Porter, L | 2 |
| Blayney, D | 1 |
| Sinoff, C | 1 |
| Wheeler, H | 1 |
| Simeone, JF | 1 |
| Knight, RD | 2 |
| Kise, H | 1 |
| Kobayashi, K | 1 |
| Arima, K | 1 |
| Yanagawa, M | 1 |
| Tochigi, H | 1 |
| Kawamura, J | 1 |
| Hioki, T | 1 |
| Sugiura, Y | 1 |
| Ford, JF | 1 |
| Theriault, R | 1 |
| Bankhead, C | 1 |
| Siris, ES | 1 |
| Gineyts, E | 1 |
| McBride, G | 1 |
| Lissoni, P | 1 |
| Cazzaniga, M | 2 |
| Perego, MS | 1 |
| Brivio, F | 1 |
| Fumagalli, L | 1 |
| Tancini, G | 1 |
| Strang, P | 1 |
| Hultborn, R | 1 |
| Gundersen, S | 1 |
| Rydén, S | 1 |
| Holmberg, E | 1 |
| Carstensen, J | 1 |
| Wallgren, UB | 1 |
| Kilany, S | 1 |
| Blomqvist, C | 1 |
| Elomaa, I | 1 |
| Oura, S | 2 |
| Sakurai, T | 2 |
| Yoshimura, G | 1 |
| Tamaki, T | 1 |
| Umemura, T | 1 |
| Kokawa, Y | 2 |
| Kao, G | 1 |
| Rubiales, AS | 1 |
| Centeno, C | 1 |
| Boissier, S | 1 |
| Magnetto, S | 1 |
| Frappart, L | 1 |
| Cuzin, B | 1 |
| Ebetino, FH | 1 |
| Clezardin, P | 1 |
| Piovesan, A | 1 |
| Berruti, A | 2 |
| Torta, M | 2 |
| Cannone, R | 1 |
| Sperone, P | 2 |
| Panero, A | 1 |
| Gorzegno, G | 1 |
| Termine, A | 1 |
| Dogliotti, L | 2 |
| Angeli, A | 2 |
| Fasolis, G | 1 |
| Fontana, D | 1 |
| Kage, K | 1 |
| Nagahama, T | 1 |
| Sekine, I | 1 |
| Maruyama, M | 1 |
| Ogata, E | 1 |
| Vinholes, JJ | 1 |
| Abbey, ME | 1 |
| Bloomfield, DJ | 1 |
| Coukell, AJ | 1 |
| Markham, A | 1 |
| Graziano, F | 1 |
| Ligi, M | 1 |
| Rossi, D | 1 |
| Ficarelli, R | 1 |
| Cömlekçi, A | 1 |
| Biberoglu, S | 1 |
| Hekimsoy, Z | 1 |
| Okan, I | 1 |
| Pişkin, O | 1 |
| Sekeroglu, B | 1 |
| Alakavuklar, M | 1 |
| Kokufu, I | 3 |
| Kim, YH | 3 |
| Peng, YF | 1 |
| Fukuda, K | 3 |
| Yamamoto, M | 3 |
| Yano, T | 3 |
| Kitano, H | 3 |
| Fulfaro, F | 2 |
| Polastri, D | 1 |
| Laffranchi, A | 1 |
| Moliterni, A | 1 |
| Adamietz, IA | 1 |
| Broyles, DL | 1 |
| Nielsen, RG | 1 |
| Bussett, EM | 1 |
| Lu, WD | 1 |
| Mizrahi, IA | 1 |
| Nunnelly, PA | 1 |
| Ngo, TA | 1 |
| Noell, J | 1 |
| Christenson, RH | 1 |
| Kress, BC | 1 |
| Houston, S | 2 |
| Rubens, RD | 6 |
| Kandra, A | 1 |
| Maekawa, Y | 1 |
| Furuya, Y | 1 |
| Toyokawa, A | 1 |
| Kinugasa, T | 1 |
| Fukano, S | 1 |
| Sekimoto, K | 1 |
| Diel, IJ | 5 |
| Bartl, R | 1 |
| Burckhardt, P | 6 |
| Fleisch, H | 1 |
| Kyle, RA | 1 |
| Koeberle, D | 3 |
| Thuerlimann, B | 3 |
| Senn, HJ | 2 |
| Sims, EC | 1 |
| Rogers, PB | 1 |
| Besser, GM | 1 |
| Plowman, PN | 1 |
| Bacchus, L | 2 |
| Thürlmann, B | 1 |
| Zeevaart, JR | 1 |
| Jarvis, NV | 1 |
| Louw, WK | 1 |
| Jackson, GE | 1 |
| Cukrowski, I | 1 |
| Mouton, CJ | 1 |
| Lacombe, D | 1 |
| Bastit, P | 1 |
| Wildiers, J | 1 |
| Michel, J | 1 |
| Leonard, R | 1 |
| Nortier, J | 1 |
| Mignolet, F | 1 |
| Akyüz, C | 1 |
| Yalçin, B | 1 |
| Kutluk, T | 1 |
| Cila, A | 1 |
| Büyükpamukçu, M | 1 |
| Hsu, T | 1 |
| Cohen, H | 1 |
| Alferiev, IS | 1 |
| Mönkkönen, J | 1 |
| Seibel, MJ | 1 |
| Pinto, T | 1 |
| Ezra, A | 1 |
| Solomon, V | 1 |
| Stepensky, D | 1 |
| Sagi, H | 1 |
| Ornoy, A | 1 |
| Patlas, N | 1 |
| Hägele, G | 1 |
| Hoffman, A | 1 |
| Breuer, E | 1 |
| Golomb, G | 1 |
| Nakaguchi, K | 1 |
| Furukawa, J | 1 |
| Shingai, T | 1 |
| Azama, T | 1 |
| Yoshioka, S | 1 |
| Katsumoto, Y | 1 |
| Morimoto, T | 1 |
| Okajima, S | 1 |
| Sue, F | 1 |
| Lortholary, A | 1 |
| Jadaud, E | 1 |
| Berthaud, P | 1 |
| Barişta, I | 1 |
| Hortobagyi, G | 2 |
| Weeks, JC | 1 |
| Desch, CE | 1 |
| Smith, TJ | 1 |
| Mellars, K | 1 |
| Heffernan, M | 1 |
| Gessner, U | 1 |
| Horisberger, B | 1 |
| Paule, B | 1 |
| Clerc, D | 1 |
| Brion, N | 1 |
| Kusama, M | 2 |
| Kaise, H | 2 |
| Nakayama, S | 2 |
| Ota, D | 2 |
| Aoki, T | 2 |
| Koyanagi, Y | 2 |
| Matsunaga, T | 1 |
| Nakamura, Y | 1 |
| Pawlega, J | 1 |
| Adamczyk, A | 1 |
| Solomayer, EF | 2 |
| Bastert, G | 2 |
| Jin, M | 1 |
| Yang, B | 1 |
| Lei, L | 1 |
| Yoshimasu, T | 1 |
| Nakamura, T | 1 |
| Ohta, F | 1 |
| Naito, Y | 1 |
| Mercadante, S | 2 |
| Salai, M | 1 |
| Penichal, I | 1 |
| Dudkiewitz, I | 1 |
| Chechick, A | 1 |
| Taniguchi, H | 2 |
| Kitazawa, S | 1 |
| Olson, KB | 1 |
| Pienta, KJ | 1 |
| Nomizu, T | 1 |
| Yabuta, T | 1 |
| Katagata, N | 1 |
| Watanabe, F | 1 |
| Yamaki, Y | 1 |
| Nihei, M | 1 |
| Tsuchiya, A | 1 |
| Takenoshita, S | 1 |
| Abe, R | 1 |
| Nikolic-Tomasević, Z | 1 |
| Jelic, S | 1 |
| Popov, I | 1 |
| Radosavljević, D | 1 |
| Morley, W | 1 |
| Dreicer, R | 1 |
| Kuross, SA | 1 |
| Mackie, PS | 1 |
| Fisher, JL | 1 |
| Zhou, H | 1 |
| Choong, PF | 1 |
| Johnson, IS | 1 |
| Massoudi, S | 1 |
| Brenner, W | 1 |
| Czech, N | 1 |
| Kampen, WU | 1 |
| Henze, E | 1 |
| Johnston, SR | 1 |
| Mishra, A | 1 |
| Wong, L | 1 |
| Jonklaas, J | 1 |
| Sonnemann, J | 1 |
| Eckervogt, V | 1 |
| Truckenbrod, B | 1 |
| Boos, J | 1 |
| Winkelmann, W | 1 |
| van Valen, F | 1 |
| Beusterien, KM | 1 |
| Hill, MC | 1 |
| Ackerman, SJ | 1 |
| Zacker, C | 2 |
| Vitale, G | 1 |
| Fonderico, F | 1 |
| Martignetti, A | 1 |
| Caraglia, M | 1 |
| Ciccarelli, A | 1 |
| Nuzzo, V | 1 |
| Abbruzzese, A | 1 |
| Lupoli, G | 1 |
| Stagno, F | 1 |
| Guglielmo, P | 1 |
| Consoli, U | 1 |
| Pafumi, M | 1 |
| Giustolisi, R | 1 |
| Ali, SM | 1 |
| Esteva, FJ | 1 |
| Knight, R | 1 |
| Jones, J | 1 |
| Villari, P | 1 |
| Ferrera, P | 1 |
| Dabbene, M | 1 |
| Clohisy, DR | 1 |
| O' Keefe, PF | 1 |
| Ramnaraine, ML | 1 |
| Rudlowski, C | 1 |
| Rath, W | 1 |
| Becker, AJ | 1 |
| Wiestler, OD | 1 |
| Buttner, R | 1 |
| DesHarnais Castel, L | 1 |
| Bajwa, K | 1 |
| Markle, JP | 1 |
| Janssen van Doorn, K | 1 |
| Neyns, B | 1 |
| Van der Niepen, P | 1 |
| Verbeelen, D | 1 |
| Jagdev, SP | 1 |
| Purohit, P | 1 |
| Heatley, S | 1 |
| Herling, C | 1 |
| Yokoyama, H | 1 |
| Nakatsuka, K | 1 |
| Shoji, T | 1 |
| Kawasaki, I | 1 |
| Inaba, M | 1 |
| Nishizawa, Y | 1 |
| Stajszczyk, M | 1 |
| Mykała-Cieśla, J | 1 |
| Misaka, T | 1 |
| Matunaga, T | 1 |
| Marcus, CS | 1 |
| Saeed, S | 1 |
| Mlikotic, A | 1 |
| Mishkin, F | 1 |
| Pham, HL | 1 |
| Javellana, T | 1 |
| Diestelhorst, S | 1 |
| Minami, C | 1 |
| Groff, L | 1 |
| Zecca, E | 1 |
| Brunelli, C | 1 |
| Boffi, R | 1 |
| Panzeri, C | 1 |
| Adam, Z | 1 |
| Wong, R | 1 |
| Wiffen, PJ | 1 |
| Dardoufas, CE | 1 |
| Antypas, CE | 1 |
| Sandilos, PH | 1 |
| Matsopoulos, GK | 1 |
| Sun, YC | 1 |
| Geldof, AA | 1 |
| Newling, DW | 1 |
| Rao, BR | 1 |
| Kellihan, MJ | 1 |
| Mangino, PD | 1 |
| Leyvraz, S | 3 |
| Hess, U | 1 |
| Flesch, G | 1 |
| Bauer, J | 1 |
| Hauffe, S | 1 |
| James, I | 1 |
| Rodger, A | 1 |
| Leonard, RC | 1 |
| Zwinderman, AH | 1 |
| Aaronson, NK | 1 |
| van Emmerik, B | 1 |
| van Dam, FS | 1 |
| van den Bos, B | 1 |
| Dodwell, DJ | 3 |
| Abbas, SK | 1 |
| Morton, AR | 2 |
| Daley-Yates, PT | 1 |
| Pongchaidecha, M | 1 |
| Thiébaud, D | 3 |
| von Fliedner, V | 2 |
| Perey, L | 2 |
| Cornu, P | 1 |
| Thiébaud, S | 1 |
| Dirix, LY | 1 |
| Dodwell, D | 1 |
| Becher, R | 1 |
| White, GK | 1 |
| Van Oosterom, A | 1 |
| Warrell, RP | 2 |
| Klenner, T | 1 |
| Wingen, F | 3 |
| Keppler, BK | 1 |
| Krempien, B | 2 |
| Schmähl, D | 2 |
| Nishijima, Y | 1 |
| Nemoto, R | 1 |
| Koiso, K | 1 |
| Kefford, R | 1 |
| Stuart-Harris, R | 1 |
| Pelger, RC | 1 |
| Lycklama à Nijeholt, AA | 1 |
| Cantwell, B | 1 |
| Harris, AL | 1 |
| Harinck, HI | 1 |
| Vermey, P | 1 |
| Elte, JW | 1 |
| Borkowski, A | 2 |
| Cleeren, A | 1 |
| Cantrill, JA | 1 |
| Pillai, GV | 1 |
| McMahon, A | 1 |
| Anderson, DC | 1 |
| Williams, MR | 1 |
| Mohajer, MP | 1 |
| Woll, PJ | 1 |
| Miles, M | 1 |
| Scrivener, W | 1 |
| Jaeger, P | 1 |
| Jacquet, AF | 1 |
| Glibert, F | 1 |
| Nejai, S | 1 |
| Yates, AJ | 1 |
| Murray, RM | 1 |
| Jerums, GJ | 1 |
| Eichmann, T | 1 |
| Manegold, C | 1 |
| Radl, J | 1 |
| Croese, JW | 1 |
| Zurcher, C | 1 |
| van den Enden-Vieveen, MH | 1 |
| Brondijk, RJ | 1 |
| Kazil, M | 1 |
| Haaijman, JJ | 1 |
| Reitsma, PH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Randomized Study of High-Dose Ketoconazole With or Without Alendronate Sodium in Patients With Androgen-Independent Metastastic Adenocarinoma of the Prostate[NCT00019695] | Phase 2 | 0 participants | Interventional | 1999-03-31 | Terminated | ||
| Atrasentan and Zometa for Men With Androgen Independent Prostate Cancer Metastatic to Bone: A Randomized Pilot Study[NCT00181558] | Phase 2 | 44 participants | Interventional | 2001-12-31 | Completed | ||
| A Randomized Double-Blind, Placebo-Controlled Phase III Study of Early Versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men With Prostate Cancer Metastatic to Bone[NCT00079001] | Phase 3 | 645 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous Bisphosphonates[NCT00104650] | Phase 2 | 111 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Randomized Placebo-Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone Alone in Patients With Hormone Refractory Metastatic Prostate Cancer and Pain[NCT00003232] | Phase 3 | 227 participants (Actual) | Interventional | 1997-11-24 | Completed | ||
| A Phase III, Multicenter, Randomized, Controlled Study of Maximum Androgen Blockade With vs. Without Zoledronic Acid in Prostatic Cancer Patients With Metastatic Bone Disease[NCT00685646] | Phase 3 | 227 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| A Randomised Phase II Feasibility Study of Docetaxel (Taxotere®) Plus Prednisolone vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Zoledronic Acid (Zometa®) vs. Docetaxel (Taxotere®) Plus Prednisolone Plus Strontium-89 vs. Docetaxel (Taxotere®) Plus Pred[NCT00554918] | Phase 2 | 300 participants (Anticipated) | Interventional | 2005-02-28 | Completed | ||
| A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer[NCT00321620] | Phase 3 | 1,904 participants (Actual) | Interventional | 2006-04-01 | Completed | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41[NCT00216060] | Phase 3 | 63 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to Terminated due to low accrual) | ||
| STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial[NCT00268476] | Phase 2/Phase 3 | 11,992 participants (Actual) | Interventional | 2005-07-08 | Active, not recruiting | ||
| Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study[NCT02480634] | Phase 4 | 280 participants (Anticipated) | Interventional | 2019-06-30 | Not yet recruiting | ||
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| An International, Multicenter, Non-Randomized, Open-Labeled Study to Evaluate the Efficacy of Lower Dose Dexamethasone/Thalidomide and Higher Frequency ZOMETA(TM) in the Treatment of Previously Untreated Patients With Multiple Myeloma[NCT00263484] | Phase 2 | 56 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Early Initiated Individualized Physical Training in Newly Diagnosed Multiple Myeloma Patients; Effects on Physical Function, Physical Activity, Quality of Life, Pain, and Bone Disease.[NCT02439112] | 102 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone[NCT00760370] | Phase 2 | 60 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Impact of Neoadjuvant Chemotherapy With or Without Zometa on Occult Micrometastases and Bone Density in Women With Locally Advanced Breast Cancer[NCT00242203] | Phase 2 | 120 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression[NCT00001916] | 17 participants | Observational | 1999-03-31 | Completed | |||
| Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease (PROMISSeD Trial)[NCT05534321] | Phase 1/Phase 2 | 74 participants (Anticipated) | Interventional | 2022-08-29 | Recruiting | ||
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Overall survival (OS) was defined as the time from randomization to death of any cause. Surviving patients were censored at the date of last follow-up. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 37.9 |
| Placebo + Androgen Deprivation Therapy | 36.0 |
"Progression Free Survival (PFS) was defined as the time from registration until disease progression or death, whichever occurs first. The median PFS with 95% CI was estimated using the Kaplan-Meier method.~Progression is defined as one or more of the following: new bone metastases, biochemical progression of PSA, treatment with radiation therapy while on treatment." (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 10.6 |
| Placebo + Androgen Deprivation Therapy | 9.2 |
Time to first skeletal related event (SRE) was defined as the time from randomization to first skeletal event. Skeletal events are defined as radiation to bone, clinical fracture, surgery to bone and spinal cord compression and death due to prostate cancer. The median with 95% CI was estimated using the Kaplan Meier method. (NCT00079001)
Timeframe: Up to 10 years
| Intervention | months (Median) |
|---|---|
| Zoledronic Acid + Androgen Deprivation Therapy | 31.9 |
| Placebo + Androgen Deprivation Therapy | 28.8 |
Time from the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) to the 1st occurrence of uNTx above 50 nmol BCE/mmol up to week 25. For participants who remained below 50 nmol BCE/mmol, the time is censored at the time of last evaluation of uNTx up to week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 25 |
| Denosumab 180 mg Q12W | 32 |
| Denosumab 180 mg Q4W | 35 |
Occurrence of hypercalcemia at grade 3 or 4 according to CTCAE v3 criteria (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 0 |
| Denosumab 180 mg Q12W | 0 |
| Denosumab 180 mg Q4W | 0 |
Percent change from baseline to week 25 in Type I serum C-Telopeptide (CTX), calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -40.68 |
| Denosumab 180 mg Q12W | -76.74 |
| Denosumab 180 mg Q4W | -68.39 |
Percent change from baseline to week 25 urinary N-telopeptide (uNTX) calculated using ((week 25 value - baseline value) / baseline value ) x 100. (NCT00104650)
Timeframe: Baseline, week 25
| Intervention | Percent change (Mean) |
|---|---|
| Bisphosphonate IV Q4W | -32.91 |
| Denosumab 180 mg Q12W | -69.09 |
| Denosumab 180 mg Q4W | -41.68 |
Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Time from study day 1 to first Skeletal Related Event (SRE), defined as >1 of the following: pathological bone fracture, spinal cord compression, surgery or radiation therapy to bone (including the use of radioisotopes). (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 6 |
| Denosumab 180 mg Q12W | 4 |
| Denosumab 180 mg Q4W | 2 |
Kaplan-Meier estimate of the median time from enrollment to the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) up to week 25. For participants whose uNTx does not go below 50 nM BCE/mM creatinine, the time is censored at time of last evaluation of uNTx by week 25. (NCT00104650)
Timeframe: Day 1, week 25
| Intervention | Days (Median) |
|---|---|
| Bisphosphonate IV Q4W | 65 |
| Denosumab 180 mg Q12W | 9 |
| Denosumab 180 mg Q4W | 10 |
Urinary N-telopeptide (uNTx) corrected by creatinine (uNTx/Cr) < 50 nmol/mmol at week 13. (NCT00104650)
Timeframe: 13 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 10 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 28 |
Urinary N-telopeptide (uNTX) corrected by creatinine < 50 nmol/mmol at week 25. (NCT00104650)
Timeframe: 25 weeks
| Intervention | Participants (Number) |
|---|---|
| Bisphosphonate IV Q4W | 13 |
| Denosumab 180 mg Q12W | 21 |
| Denosumab 180 mg Q4W | 23 |
Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported. (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Days (Median) |
|---|---|
| Zoledronic Acid | 521.0 |
| Denosumab | 629.0 |
"Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.~This outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events." (NCT00321620)
Timeframe: Up to 40.5 months
| Intervention | Events (Number) |
|---|---|
| Zoledronic Acid | 584 |
| Denosumab | 494 |
Number of participants experiencing a SRE(skeletal-related event) or death occurred, cumulative from each arm ( a daily oral dose of 30 mg risedronate, or placebo) (NCT00216060)
Timeframe: 36 months
| Intervention | participants (Number) |
|---|---|
| Risedronate Arm | 11 |
| Placebo Arm | 13 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate Arm | 50 |
| Placebo Arm | 29 |
(NCT00216060)
Timeframe: 36 months
| Intervention | percentage of participants (Number) |
|---|---|
| Risedronate | 72.5 |
| Placebo | 71.5 |
"Urine total DPD median in response to treatment on both study arms at week 24. compare median from baseline and week 24.~Deoxypyridinoline (DPD) is measured in hydrolyzed urine samples using high-performance liquid chromatography technique. After extraction of the cross-links and elimination of the urine impurities by a Bio-Rad SPE cartridge (Bio-Rad Laboratories, Hercules, CA), total DPD is eluted from reverse-phase high-performance liquid chromatography by ion pair chromatography with isocratic elution.~The compounds are detected as a result of their natural fluorescence with a fluorescence detector" (NCT00216060)
Timeframe: 24 weeks
| Intervention | nmol/mmol creatinine (Median) | |
|---|---|---|
| week 24 | baseline | |
| Placebo Arm | 12.62 | 10.12 |
| Risedronate Arm | 6.91 | 8.83 |
Serum BAP median changes between baseline and week 24. The Ostase assays are performed with an access immunoassay system, which is an assay of serum samples that provides a quantitative measurement of bone alkaline phosphatase (BAP). A mouse monoclonal antibody specific to BAP is added to a re-action vessel with paramagnetic particles coated with goat antimouse polyclonalantibody.Calibrators,controls,andsamplescontainingBAP are added to the coated particles and bind to the anti-BAP monoclonal antibody. After the formation of a solid phase/capture antibody/BAP complex, separation in a magnetic field and washing remove materials not bound to the solid phase. A chemiluminescent substrate, LumiPhos 530, is added to the reaction vessel, and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of BAP in the sample. The amount of analyte in thesample is determined from a stored multipoint calibration curve (NCT00216060)
Timeframe: 24 week
| Intervention | ng/mL (Median) | |
|---|---|---|
| 24 week | baseline | |
| Placebo Arm | 13.16 | 19.50 |
| Risedronate Arm | 9.5 | 20.95 |
Serum Osteocalcin (OC) medians between baseline and 24 weeks areperformed with the Elecsys 2010 automated analyzer, which uses an electrochemiluminescence immunoassay technique for the in vitro quantitative determination of serum total osteocalcin in humanserum. The assay uses a sandwich test principle in which afirst biotinylated monoclonal antibody recognizing N-MID osteocalcin and a second monoclonal antibody against N-MID osteocalcin labeled with ruthenium are incubated with 20mL of serum. After a first incubation, streptavidin-coated microparticles are added for a second incubation, and the complex becomes bound to the solid phase by interaction of biotin and streptavidin.These microparticles are then magnetically captured onto the surface of an electrode. Application of a voltage on this electrode induces chemiluminescent emission, which is measured by a photomultiplierand compared with a calibration curve that is generated in aninstrument-specific manner by 2-point calibration. (NCT00216060)
Timeframe: 24 week
| Intervention | ug/L (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 27.35 | 18.24 |
| Risedronate Arm | 11.88 | 20.08 |
"Urine N-telopeptide (NTX) median changes between baseline and week 24. The assays are performed with the NTx Reagent Pack kit from Ortho-Clinical Diagnostics (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK), which is a kit designed for the quantitative determination of N-terminal telopeptide (NTx) in human urine on the automated Vitros Immunodiagnostic System ECi (Ortho-Clinical Diagnostics/Johnson & Johnson, Amersham, UK). A competitive immunoassay technique is used. This depends on competition between NTx present in the sample and a synthetic NTx peptide coated on the wells for binding by a horseradish peroxidase (HRP)-labeled antibody conjugate (mouse monoclonal anti-NTx). The conjugate is captured by the peptide coated on the wells; unbound materials are removed by washing.~The bound HRP conjugate is measured by a luminescent reaction." (NCT00216060)
Timeframe: 24 week
| Intervention | nmol BCE/mmol creatinine (Median) | |
|---|---|---|
| at 24 week | baseline | |
| Placebo Arm | 62.95 | 48.08 |
| Risedronate Arm | 20.63 | 41.33 |
67 reviews available for pamidronate and Bone Cancer
| Article | Year |
|---|---|
Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis.
Topics: Bone Neoplasms; Cancer Pain; Diphosphonates; Humans; Pamidronate; Quality of Life | 2021 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the | 2020 |
Adverse events associated with bone-directed therapies in patients with cancer.
Topics: Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; | 2022 |
Denosumab versus bisphosphonates for the treatment of bone metastases from solid tumors: a systematic review.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; | 2019 |
Treatment of multiple myeloma bone disease: experimental and clinical data.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Diseases; Bone Neoplasms; De | 2015 |
Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone and Bones; Bone Density Cons | 2015 |
Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; | 2015 |
Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imi | 2015 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic A | 2016 |
Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diph | 2009 |
Pamidronate-induced kidney injury in a patient with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Gl | 2009 |
Osteonecrosis or metastases of the jaw or both? Case report and review of the literature.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Dipho | 2010 |
[Bisphosphonates in adjuvant therapy of breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Controlled Clini | 2010 |
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinica | 2011 |
[Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Ne | 2011 |
Renal complications from bisphosphonate treatment.
Topics: Acute Kidney Injury; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Kidney; Kidney Diseases; Ne | 2012 |
Bone-targeted agents: preventing skeletal complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Tria | 2012 |
[Pamidronate in the treatment of bone metastases from breast cancer].
Topics: Ambulatory Care; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; D | 2002 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonat | 2002 |
Bisphosphonates and metastatic breast carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycopr | 2003 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; | 2002 |
Bisphosphonate therapy in the oncology setting.
Topics: Administration, Oral; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Huma | 2003 |
Safety and convenience of a 15-minute infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandr | 2004 |
Bisphosphonates in the treatment of skeletal metastases.
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Pamidronate; Zoledronic Acid | 2004 |
Management of bone metastases in breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; | 2005 |
Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clin | 2004 |
The role of bisphosphonates in the management of advanced cancer with a focus on non-small-cell lung cancer. Part 1: Mechanisms of action, role of biomarkers and preclinical applications.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; | 2005 |
Bisphosphonates in breast cancer.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Dose-Respons | 2005 |
Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
Topics: Antineoplastic Agents; Aromatase Inhibitors; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Chem | 2005 |
Should oral bisphosphonates be standard of care in women with early breast cancer?
Topics: Antimetabolites; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphospho | 2005 |
New therapeutic agents for the treatment of bone diseases.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Bo | 2005 |
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind | 2005 |
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Dental Care for Chronically | 2006 |
[Clinical study of bisphosphonates for bone metastasis in breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fracture | 2007 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neop | 2008 |
Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2008 |
Progress in the treatment and palliation of advanced breast cancer: does the dose of pamidronate determine its effects?
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Female; Humans; Hypercal | 1994 |
[Pharmacologic therapy of bone tissue changes due to hematologic malignancies and bone metastasis].
Topics: Bone Neoplasms; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasms; Osteo | 1994 |
Bone and cancer: pathophysiology and treatment of metastases.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms | 1995 |
[Bisphosphonates in the treatment concept of metastatic breast carcinoma].
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemi | 1996 |
Use of bisphosphonates in cancer patients.
Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid | 1996 |
Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article.
Topics: Analgesia; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonate | 1996 |
Rationale for the use of bisphosphonates in breast cancer.
Topics: Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Clodronic Acid; Cost-Benefit Analysis; Diphosphon | 1996 |
Bisphosphonate therapy in metastatic breast cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; D | 1996 |
Bisphosphonates and breast carcinoma.
Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic | 1997 |
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Evidence | 1998 |
Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Hypercalcemia; Neopl | 1998 |
Aredia: the once-monthly infusion for the treatment of bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1998 |
[Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; | 1998 |
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodron | 1998 |
Bisphosphonates in clinical oncology. The development of pamidronate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Diseases; Bone Neoplasms | 1999 |
[Bisphosphonates and bone metastases].
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonat | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasm | 2000 |
[Monitoring of bone metastases].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Injections, Intravenous; Neoplasms, S | 2000 |
Bisphosphonates and breast carcinoma: present and future.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Osteolysis; Pamidronate | 2000 |
Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Pamidrona | 2000 |
[Skeletal bone metastasis--current concepts of diagnosis and treatment].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Pamidronate | 1999 |
[Bisphosphonate for treatment of advanced breast cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Clinical Trials as | 2000 |
[Therapeutic value of aredia in treatment of breast carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Palliative | 2000 |
Systemic treatment of metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aromatase Inh | 2001 |
Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 2000 |
[Bisphosphonates in the treatment of breast carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Hum | 2001 |
Bisphosphonates for the relief of pain secondary to bone metastases.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Eti | 2002 |
Pamidronate.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Osteitis Deformans; | 1992 |
Bone metastases and tumor-induced hypercalcemia.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho | 1992 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
Bone metastases and breast cancer.
Topics: Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium-Bin | 1985 |
80 trials available for pamidronate and Bone Cancer
| Article | Year |
|---|---|
Adjuvant therapy with carboplatin and pamidronate for canine appendicular osteosarcoma.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2015 |
Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy.
Topics: Adolescent; Adult; Bone Density Conservation Agents; Bone Neoplasms; Child; Diphosphonates; Female; | 2014 |
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
Topics: Administration, Intravenous; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Ne | 2014 |
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplas | 2016 |
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collage | 2008 |
Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; H | 2009 |
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; | 2011 |
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates.
Topics: Aged; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Neoplasms; Collagen Type I; Diphosphon | 2011 |
Addition of pamidronate to chemotherapy for the treatment of osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Diphos | 2011 |
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fea | 2013 |
Bisphosphonates and metastatic breast carcinoma.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Forecasting; Glycopr | 2003 |
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Dose-Respo | 2003 |
Efficacy of zoledronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Humans; Imida | 2002 |
An intra-patient dose-escalation study of disodium pamidronate plus radiotherapy versus radiotherapy alone for the treatment of osteolytic metastases. Monitoring of recalcification using image-processing techniques.
Topics: Adult; Antineoplastic Agents; Bone Density; Bone Neoplasms; Bone Regeneration; Chemotherapy, Adjuvan | 2003 |
Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessmen
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphosphonates; Female; Fo | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidaz | 2003 |
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind | 2003 |
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Re | 2004 |
Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions.
Topics: Bone Neoplasms; Breast Neoplasms; Canada; Diphosphonates; Double-Blind Method; Female; Humans; Imida | 2004 |
[Efficacy and feasibility evaluation in long term pamidronate treatment of bone metastases].
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Feasib | 2003 |
Bisphosphonate infusions: patient preference, safety and clinic use.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Confidence Intervals; Diphosp | 2004 |
Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer.
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Greece; Huma | 2004 |
[Pamidronate in treatment of pain caused by bone metastasis].
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Fem | 2004 |
[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Comb | 2005 |
[Phase II randomized clinical trail of zoledronic acid in treating metastatic bone pain of malignancy].
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; | 2005 |
A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Area | 2006 |
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Br | 2006 |
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agen | 2008 |
Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type | 2007 |
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Cre | 2007 |
Does pamidronate enhance the analgesic effect of radiotherapy? A randomized trial.
Topics: Analgesia; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Pain; Pain Measurement; Pa | 2007 |
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2008 |
Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Bone Neoplasms; Bre | 1994 |
Pamidronate in the treatment of bone metastases: results of 2 dose-ranging trials in patients with breast or prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Rela | 1994 |
Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; | 1994 |
A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Topics: Bone Neoplasms; Bone Resorption; Clodronic Acid; Diphosphonates; Double-Blind Method; Humans; Hyperc | 1995 |
Palliative pamidronate treatment in patients with bone metastases from breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; | 1993 |
Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease Progre | 1994 |
Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein.
Topics: Bone Neoplasms; Calcium; Diphosphonates; Humans; Hypercalcemia; Infusions, Intravenous; Kidney Tubul | 1994 |
High-dose intravenous pamidronate for metastatic bone pain.
Topics: Bone and Bones; Bone Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hy | 1994 |
Disodium pamidronate in the treatment of bone metastases from breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans | 1993 |
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.
Topics: Activities of Daily Living; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relation | 1994 |
The effects of orchidectomy on skeletal metabolism in metastatic prostate cancer.
Topics: Biopsy; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Male; Orc | 1993 |
Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans | 1995 |
Treatment of tumour-induced hypercalcaemia in advanced breast cancer patients with three different doses of disodium pamidronate adapted to the initial level of calcaemia.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Drug Monitoring; Female; Hum | 1995 |
Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
Topics: Adult; Aged; Analysis of Variance; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcitriol; Ca | 1995 |
Metabolic effects of pamidronate in patients with metastatic bone disease.
Topics: Aged; Alkaline Phosphatase; Analysis of Variance; Biomarkers; Bone Development; Bone Neoplasms; Bone | 1996 |
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1996 |
Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Diphosphonates; | 1996 |
Does supportive pamidronate treatment prevent or delay the first manifestation of bone metastases in breast cancer patients?
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Mi | 1996 |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Femal | 1996 |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Femal | 1996 |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Femal | 1996 |
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Femal | 1996 |
[Bisphosphonates in the treatment concept of metastatic breast carcinoma].
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemi | 1996 |
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Disease-Fr | 1996 |
Pamidronate in the treatment of osteolytic bone metastases in breast cancer patients.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Pa | 1996 |
Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Neoplasms; Bone Resorption; Calcium; C | 1997 |
Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Osteolysis; Pain; Pamidronate; Qua | 1996 |
Comparison of assay of total and bone-specific alkaline phosphatase in the assessment of osteoblast activity in patients with metastatic bone disease.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols | 1997 |
Fitting new modalities into practice guidelines.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Data Interpretation, Statis | 1997 |
Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease.
Topics: Adult; Aged; Bone Neoplasms; Bone Resorption; Diphosphonates; Double-Blind Method; Female; Humans; M | 1997 |
Different doses of pamidronate in patients with painful osteolytic bone metastases.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Diphosphonates; Female; Humans; Male; | 1998 |
[Retardation of progression of bone metastasis in mammary carcinoma patients by intravenous pamidronate treatment: results of a randomized, controlled, multinational study].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pamidronate | 1998 |
A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast | 1998 |
[Bisphosphonates in the adjuvant therapy of breast cancer-- pathophysiology, animal models, and clinical experiences].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; | 1998 |
Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Analgesics; Anti-Inflammatory Agents; Antine | 1999 |
Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Canada; Cancer Care Facilities | 1999 |
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; | 2000 |
Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind | 2000 |
[The evaluation of pamidronate therapy for bone metastases from breast cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; | 2000 |
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neop | 2001 |
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Analgesics; Anti-Inflammatory Agents; Bone Neoplasms; Bone | 2001 |
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imid | 2001 |
Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
Topics: Administration, Oral; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Bone Neoplasm | 2001 |
The role of disodium pamidronate in the management of bone pain due to malignancy.
Topics: Adult; Aged; Analgesics; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphospho | 2001 |
Use of image processing techniques to assess effect of disodium pamidronate in conjunction with radiotherapy in patients with bone metastases.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Diphospho | 2002 |
Pamidronate.
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Humans; Hypercalcemia; Osteitis Deformans; | 1992 |
The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphos | 1991 |
Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.
Topics: Alkaline Phosphatase; Bone Neoplasms; Bone Resorption; Calcium; Creatinine; Diphosphonates; Humans; | 1992 |
Hypercalcemia and bone metastases in breast cancer.
Topics: Alendronate; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Hyper | 1990 |
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosph | 1987 |
[Treatment of neoplastic hypercalcemia using single-infusion diphosphonate].
Topics: Adult; Aged; Bone Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Huma | 1988 |
214 other studies available for pamidronate and Bone Cancer
| Article | Year |
|---|---|
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms | 2022 |
Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Denosumab; Diphosphonates; Humans; | 2022 |
Bisphosphonate type-dependent cell viability suppressive effects of carbon nanohorn-calcium phosphate-bisphosphonate nanocomposites.
Topics: Animals; Bone Neoplasms; Bone Resorption; Calcium Phosphates; Carbon; Cell Survival; Diphosphonates; | 2022 |
Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy; Denosum | 2020 |
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Medic | 2017 |
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as To | 2017 |
Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Female; Humans; Hypercalcemia; K | 2018 |
A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy.
Topics: Bone Neoplasms; Calcium; Humans; Hypercalcemia; Hypocalcemia; Male; Middle Aged; Pamidronate; Risk F | 2019 |
Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study.
Topics: Bone Neoplasms; Bone Resorption; Calcification, Physiologic; Cell Adhesion; Diphosphonates; Drug-Rel | 2013 |
Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin.
Topics: Animals; Antibiotics, Antineoplastic; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, T | 2014 |
Use of intravenous bisphosphonates in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Hu | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Dens | 2014 |
Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
Topics: Aged; Ambulatory Care; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Canada; C | 2014 |
Quality and Outcomes of Treatment of Hypercalcemia of Malignancy.
Topics: Aged; Bone Neoplasms; Calcitonin; Diphosphonates; Diuretics; Female; Glucocorticoids; Humans; Hyperc | 2015 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carc | 2016 |
White Knuckling.
Topics: Adaptation, Psychological; Aged; Antineoplastic Agents; Attitude to Death; Bone Neoplasms; Breast Ne | 2016 |
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2016 |
Extravasation reactions associated with the administration of pamidronate: 11 cases (2008-2013).
Topics: Animals; Blood Vessels; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Dog Diseas | 2017 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; | 2016 |
SAFETY AND TOXICITY OF AN ACCELERATED COARSELY FRACTIONATED RADIATION PROTOCOL FOR TREATMENT OF APPENDICULAR OSTEOSARCOMA IN 14 DOGS: 10 GY × 2 FRACTIONS.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates | 2016 |
Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Doxorubicin; Female; Mice; Mice, Inb | 2016 |
Chronic recurrent multifocal osteomyelitis (CRMO) - advancing the diagnosis.
Topics: Adolescent; Anti-Bacterial Agents; Arthritis, Juvenile; Biopsy; Bone Density Conservation Agents; Bo | 2016 |
Use of intravenous bisphosphonates in older women with breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neopl | 2008 |
Bisphosphonate-associated osteonecrosis of the jaw: successful treatment at 2-year follow-up.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Debrideme | 2008 |
Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Femal | 2008 |
Clinical and radiologic response in patients with bone metastases managed with combined radiotherapy and bisphosphonates.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Iba | 2008 |
Acute retinal pigment epithelial detachment secondary to pamidronate administration.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fluorescein Angiography; Humans; I | 2009 |
[Efficiency of second-generation bisphosphonate in treating patients with prostate cancer and bone metastases].
Topics: Bone Neoplasms; Diphosphonates; Humans; Male; Pamidronate; Prostatic Neoplasms; Treatment Outcome | 2008 |
Rapid pain relief and marked sclerotic change of multiple bone metastases from a synovial sarcoma after treatment with intravenous pamidronate and chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neopla | 2009 |
Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Comorbidi | 2010 |
Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Female; Hu | 2009 |
Percutaneous cementoplasty in the palliative, multimodal treatment of primary bone tumors of the distal aspect of the radius in four dogs.
Topics: Animals; Bone Cements; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Dog Disease | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; | 2009 |
Routine use of pamidronate in NSCLC patients with bone metastasis: results from a retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Ad | 2009 |
Prosthodontic treatment of a patient with bisphosphonate-induced osteonecrosis of the jaw using a removable dental prosthesis with a heat-polymerized resilient liner: a clinical report.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Denture Liners; Denture, Partial, Removable; | 2010 |
[A case of breast cancer with extensive osteonecrosis of maxilla induced by a bisphosphonate].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Maxil | 2010 |
Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis | 2010 |
Bisphosphonates for bone pain #113.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Neopla | 2010 |
Nephrotic syndrome induced by pamidronate.
Topics: Adenocarcinoma; Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Huma | 2011 |
Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone.
Topics: Alkyl and Aryl Transferases; Apoptosis; Benzamides; Bone Density Conservation Agents; Bone Neoplasms | 2011 |
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Bre | 2010 |
Skeletal imaging effects of pamidronate therapy in osteosarcoma patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Neoplasms; Child; Cisplatin; Diphosphonates; Doxorubi | 2011 |
Zoledronic acid in myeloma: MRC Myeloma IX.
Topics: Administration, Oral; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodr | 2010 |
American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Ne | 2011 |
Nephrotic syndrome and renal failure in a patient with metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fatal Outcome; Female; Glomerulosclerosis, Focal S | 2011 |
Outcome after repair of a sarcoma-related pathologic fracture in dogs: a Veterinary Society of Surgical Oncology Retrospective Study.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Dogs; Doxorubicin; Fema | 2011 |
In-vivo near-infrared optical imaging of growing osteosarcoma cell lesions xenografted in mice: dual-channel quantitative evaluation of volume and mineralization.
Topics: Animals; Bone Neoplasms; Calcification, Physiologic; Diphosphonates; Feasibility Studies; Inositol; | 2011 |
Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Di | 2012 |
Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Delphi Technique; Diphosphonates; Female; Humans; | 2012 |
Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; | 2012 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conserv | 2012 |
The impact of pamidronate and chemotherapy on survival times in dogs with appendicular primary bone tumors treated with palliative radiation therapy.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Dog Disea | 2012 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bre | 2013 |
Investigation of bone disease using isomerized and racemized fragments of type I collagen.
Topics: Adult; Aged; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Cells, Cultured; Collagen; | 2003 |
Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Lymp | 2002 |
[Bisphosphonates in bone metastases. Fewer fractures, less pain].
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles | 2002 |
Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain.
Topics: Analgesia; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Injections, Intravenous; P | 2002 |
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.
Topics: Animals; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Hyperalgesia; Hyperes | 2002 |
Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Hypocalcemia; Male; Middle Ag | 2003 |
Pamidronate prevents the development of skeletal metastasis in nude mice transplanted with human breast cancer cells by reducing tumor burden within bone.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Calcium; Cell Line, Tumor; Creatinin | 2003 |
Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results.
Topics: Antineoplastic Agents; Autopsy; Bone Neoplasms; Diphosphonates; Humans; Infusions, Intravenous; Male | 2003 |
Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chem | 2003 |
Bisphosphonates in prostate cancer: where are we and where should we go?
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone | 2003 |
Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Male; | 2003 |
Cancer patients with bone complications prefer infusion of zoledronic acid.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Intravenous; M | 2003 |
Utilization of palliative radiotherapy for breast cancer patients with bone metastases treated with bisphosphonates-Toronto Sunnybrook Regional Cancer Centre experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neopla | 2004 |
Bisphosphonates for men with prostate cancer: sifting through the rubble.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Humans; Male; Pain; Pall | 2003 |
Avascular necrosis of the jaws: risk factors in metastatic cancer patients.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Osteonecros | 2003 |
[Prospective study of pamidronate disodium in treatment of Paget's disease of bone].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Male; Middle Age | 2003 |
Treatment strategies for myeloma bone disease.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonanc | 2003 |
Tests for multivariate recurrent events in the presence of a terminal event.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Computer Simulation; Data Interpretation, S | 2004 |
Posterior uveitis: an under-recognized adverse effect of pamidronate: 2 case reports.
Topics: Bone Neoplasms; Bone Resorption; Carcinoma; Conjunctivitis; Diphosphonates; Fatal Outcome; Humans; M | 2003 |
[Bisphosphonate as an adjuvant therapy for the pain of bone metastases, 3 cases].
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Diphosphonates; Female; Hum | 2004 |
Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
Topics: Alendronate; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Diphosphonates; DNA Fragmentation; DN | 2004 |
Pamidronate, hypocalcemia, and calcium and vitamin D supplementation.
Topics: Bone Neoplasms; Confounding Factors, Epidemiologic; Diphosphonates; Humans; Hypocalcemia; Male; Pami | 2004 |
Dynamic contrast enhanced magnetic resonance imaging in monitoring bone metastases in breast cancer patients receiving bisphosphonates and endocrine therapy.
Topics: Adult; Aged; Anastrozole; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Goserelin; Human | 2004 |
[Effective weekly paclitaxel therapy for massive metastatic breast cancer].
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; D | 2004 |
Cost analysis of secondary prophylaxis with oral clodronate versus pamidronate in metastatic breast cancer patients.
Topics: Antimetabolites; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Chi-Square Distribution; C | 2004 |
Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.
Topics: Annexin A5; Apoptosis; Bone Neoplasms; Caspase 3; Caspases; Diphosphonates; Dose-Response Relationsh | 2004 |
Monitoring of skeletal progression of prostate cancer by GFP imaging, X-ray, and serum OPG and PTHrP.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Calcium; Carrier | 2005 |
Safety of long-term administration of bisphosphonates in elderly cancer patients.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration S | 2004 |
Inhibition of bone metastasis from breast cancer with pamidronate resulting in reduction of urinary pyridinoline and deoxypyridinoline in a rat model.
Topics: Amino Acids; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Cell Line, T | 2004 |
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazol | 2005 |
Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Topics: Ambulatory Care; Bone Neoplasms; Breast Neoplasms; Costs and Cost Analysis; Diphosphonates; Female; | 2005 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Info | 2005 |
The issue of renal safety of zoledronic acid from a nephrologist's point of view.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandr | 2005 |
"Safety and convenience of a 15-minute infusion of zoledronic acid": not so safe.
Topics: Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; Ibandr | 2005 |
Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
Topics: Administration, Oral; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort | 2005 |
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Infusions, Int | 2005 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Dis | 2005 |
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone R | 2005 |
Long-term prevention of skeletal complications by pamidronate in a patient with bone metastasis from endometrial carcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplas | 2006 |
Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplas | 2005 |
Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
Topics: Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Curettage; Diphosphon | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breas | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neopla | 2005 |
The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Cell Line, Tumor; Diphosphonates | 2006 |
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; | 2006 |
Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept?
Topics: Antineoplastic Agents; Biopsy; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Diphosph | 2006 |
[The incidence and management of bone metastasis from breast cancer].
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; | 2006 |
Case studies in metastatic bone disease: understanding the unique nature of bone loss due to malignancy.
Topics: Aftercare; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Early Diagnosis; Humans; Imidaz | 2006 |
[Retrospective evaluation of the safety of pamidronate administration at the dose of 90 mg/day/month in Japanese breast cancer patients with bone metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Combined Mo | 2006 |
Malignant hypercalcemia in pregnancy: effect of pamidronate on uterine contractions.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Breech Presentation; Cesarean Sectio | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2007 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conserv | 2006 |
Outcomes of patients with prostate cancer receiving zoledronic acid or pamidronate for prevention of skeletal-related events.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Diphosphonates; Huma | 2007 |
Short-term effects of pamidronate on bone turnover: can bone markers be considered predictive of the analgesic response?
Topics: Adult; Aged; Alkaline Phosphatase; Analgesics; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Bo | 2007 |
An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administrat | 2007 |
The role of surgery in jaw bone necrosis associated with long-term use of bisphosphonates.
Topics: Adenocarcinoma; Bone Neoplasms; Bone Plates; Bone Screws; Breast Neoplasms; Cutaneous Fistula; Dipho | 2008 |
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; M | 2008 |
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Stu | 2008 |
Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imi | 2008 |
[Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
Topics: Administration, Oral; Adult; Aged; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Female; | 1984 |
[Diphosphonates in the treatment of hypercalcemia].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Hyperparathyr | 1984 |
Progress in the treatment and palliation of advanced breast cancer. Symposium proceedings. Jerusalem, 1993.
Topics: Androstenedione; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; F | 1994 |
Intravenous aminohydroxypropylidene bisphosphonate does not modify 99mTc-hydroxymethylene bisphosphonate bone scintigraphy. A prospective study.
Topics: Aged; Bone Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, Intravenous; Male; M | 1995 |
The role of pamidronate.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pamidronate | 1994 |
Therapeutic use of bisphosphonates in oncology.
Topics: Bone Neoplasms; Diphosphonates; Humans; Osteolysis; Pamidronate | 1994 |
Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, | 1994 |
Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia.
Topics: Bone Neoplasms; Calcium; Cyclic AMP; Diphosphonates; Electrolytes; Humans; Hypercalcemia; Kidney Tub | 1993 |
Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.
Topics: Adult; Antibodies, Monoclonal; Bone Diseases, Metabolic; Bone Neoplasms; Cell Line; Diphosphonates; | 1994 |
Evaluation and treatment of hypercalcemia.
Topics: Adenoma; Aged; Bone Neoplasms; Carcinoma, Squamous Cell; Diagnosis, Differential; Diphosphonates; Fe | 1994 |
Increased growth rate and tumor burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats.
Topics: Acid Phosphatase; Animals; Bone and Bones; Bone Neoplasms; Carcinoma 256, Walker; Cell Division; Dip | 1993 |
[Results of using Aredia for hypercalcemia in oncology patients].
Topics: Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Drug Evaluation; Female; Humans; Hypercal | 1993 |
[Disodium pamidronate (APD) in the treatment of bone metastases].
Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Middle Aged; Multiple Myeloma; Pain | 1993 |
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 1995 |
Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Neoplasms; Diphosphonates; | 1996 |
Effects of bisphosphonate (pamidronate) on bone resorption resulting from metastasis of a squamous cell carcinoma: report of an autopsy case and evaluation of bone resorbing activity in an experimental animal model.
Topics: Acid Phosphatase; Aged; Animals; Bone Neoplasms; Bone Resorption; Carcinoma, Squamous Cell; Diphosph | 1996 |
Bisphosphonates in the treatment of bone diseases.
Topics: Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Fr | 1996 |
[Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Hypercalcemia; | 1996 |
Pamidronate (Aredia) and zoledronate: update on clinical results. Introduction.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Organophosphorus Compounds; Osteo | 1996 |
Pamidronate in the treatment of bone metastases--the European experience.
Topics: Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Europe; Humans; Hypercalc | 1996 |
Bisphosphonates spearhead new approach to treating bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; G | 1997 |
Breast cancer and osteolytic metastases: can bisphosphonates help?
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Infusions, Intravenous; Pamidronat | 1997 |
Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Topics: Adult; Aged; Amino Acids; Analysis of Variance; Biomarkers; Bone Neoplasms; Bone Resorption; Breast | 1997 |
Treating bone metastases: sparing the patient needless pain.
Topics: Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Pain; Pain Management; Palliative Care; Pam | 1997 |
Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Infusions, Intravenous; | 1997 |
[Bone metastases responsive to pamidronate therapy in breast cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonat | 1997 |
Pamidronate and metastatic breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pain Management; Pamidronate | 1997 |
Pamidronate and metastatic breast cancer.
Topics: Antineoplastic Agents; Bias; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pamid | 1997 |
Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices.
Topics: Bone Matrix; Bone Neoplasms; Breast Neoplasms; Calcification, Physiologic; Cell Adhesion; Cell Adhes | 1997 |
Pamidronate administration improves the secondary hyperparathyroidism due to "Bone Hunger Syndrome" in a patient with osteoblastic metastases from prostate cancer.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Calcium; Collagen; Diphosphonates; Human | 1997 |
A remarkable improvement of clinical manifestations in a breast cancer patient with widespread bone metastases after administration of pamidronate.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Lobular; Diphosphonates; Female; | 1997 |
[Bone metastases: pathogenesis and treatment with diphosphonates].
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Neoplasm Proteins; Ost | 1997 |
Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Pamidronate | 1997 |
Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Carcinoma; Diphosphonates; | 1998 |
[A case of osteolytic metastases from breast cancer effectively treated with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dr | 1998 |
Pain relief and sclerosis of bone metastases in a patient with breast cancer treated with tamoxifen, radiotherapy and pamidronate disodium: which treatment helped?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Mod | 1998 |
Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Diseases; Bon | 1998 |
[A case of gastric cancer with multiple bone metastasis treated by nocturnal 5-fluorouracil infusion combined with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Signet Ring Cell; Diphosp | 1998 |
Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease.
Topics: Aged; Amino Acids; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Chromatography, High P | 1998 |
Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 1998 |
Bisphosphonates for metastatic bone pain.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; | 1999 |
Metal-ion speciation in blood plasma incorporating the bisphosphonate, 1-hydroxy-4-aminopropilydenediphosphonate (APD), in therapeutic radiopharmaceuticals.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Holmium; Molecular Structure; Organo | 1999 |
Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Bone Resorption; Breast Neopl | 1999 |
Brief report: Medulloblastoma with widespread skeletal metastases presenting with hypercalcemia.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Cerebellar Neoplasms; Diphosphonates; Female; Hum | 1999 |
Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.
Topics: Administration, Oral; Alendronate; Animals; Antineoplastic Agents; Betaine; Bone Diseases; Bone Neop | 1999 |
[A case of multiple bone metastases from advanced breast cancer effectively treated with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1999 |
Biphosphonates and the flare phenomenon.
Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Pain | 1999 |
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Dise | 2000 |
[Biosphonates in oncology].
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Neoplasms; Osteolysis; Pain | 2000 |
[Two cases of malignancy-associated hypercalcemia from bone metastases of breast cancer successfully treated with combination therapy using pamidronate and calcitonin].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Calcitonin; Consciousness Disorders; Diphos | 2000 |
[Treatment of metastatic bone pain with Aredia(Pamidronate)].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Bone Neoplasms; Breast Neop | 1998 |
[Pamidronate therapy for lung cancer patients with bone metastasis].
Topics: Aged; Analgesics, Opioid; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Lun | 2000 |
An unusual coma after therapy for bone pain.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Coma; Diphosphonates; Female; Humans; Palliative Care; | 2000 |
[A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dr | 2000 |
Use of bisphosphonates in the treatment of prostate cancer.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Male; Pain; Palliative Care; Pamidron | 2000 |
[Two bedridden patients with bone metastases from breast cancer effectively treated with pamidronate therapy].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2000 |
[Significant therapeutic progression in tumor-induced bone diseases. This year's Robert Koch Award is awarded to Novartis Oncology].
Topics: Antineoplastic Agents; Awards and Prizes; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Pamidr | 2000 |
Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 2000 |
Tumor 'flare' hypercalcemia--an additional indication for bisphosphonates?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasm | 2001 |
Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carrier Proteins; Cell Division; Clodroni | 2001 |
Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK.
Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Drug Costs; Humans; Pain; Palliative Care; Pamidrona | 2001 |
[Bone scintigraphy in the control of bone metastasis of breast cancer during pamidronate and tamoxifen combination therapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 2001 |
Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.
Topics: Antineoplastic Agents; Bone Neoplasms; Calcitonin; Calcium Carbonate; Diphosphonates; Female; Humans | 2001 |
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Division; Clodronic Acid; Diphosphonates; DNA Fragmentat | 2001 |
The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients.
Topics: Aged; Ambulatory Care; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fema | 2001 |
Successful treatment of granulocytic sarcoma with alpha-interferon and disodium pamidronate at presentation of chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Surviva | 2001 |
Bisphosphonates may be useful in treatment of bone metastases.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials a | 2001 |
Pamidronate in incident pain due to bone metastases.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphona | 2001 |
Pamidronate decreases tumor-induced osteoclastogenesis in osteopetrotic mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Bone Resorption; Cell Count; Diphosphonat | 2001 |
Trastuzumab and breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2001 |
A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.
Topics: Antineoplastic Agents; Bone Neoplasms; Costs and Cost Analysis; Diphosphonates; Economics, Pharmaceu | 2001 |
Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Nephr | 2001 |
[Intravenous pamidronate delivery to a case with multiple bone metastasis of breast cancer].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; | 2001 |
[A case of breast cancer with multiple bone metastases that responded remarkably to doxifluridine (5'-DFUR), cyclophosphamide (CPA), medroxyprogesterone acetate (MPA) and pamidronate disodium therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 2002 |
Lack of effect of a bisphosphonate (pamidronate disodium) infusion on subsequent skeletal uptake of Sm-153 EDTMP.
Topics: Bone and Bones; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Interactions; Drug Therapy, C | 2002 |
[Is pamidronate or clodronate better?].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Hum | 2002 |
Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates.
Topics: Animals; Bone Neoplasms; Clodronic Acid; Diphosphonates; Male; Pamidronate; Prostatic Neoplasms; Rat | 1992 |
Pharmacokinetics of pamidronate in patients with bone metastases.
Topics: Aged; Aged, 80 and over; Bone Neoplasms; Diphosphonates; Female; Humans; Male; Middle Aged; Pamidron | 1992 |
Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease.
Topics: Administration, Oral; Adult; Amino Acids; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium | 1992 |
Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hy | 1991 |
The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases.
Topics: Administration, Oral; Adult; Biological Availability; Bone Neoplasms; Breast Neoplasms; Diphosphonat | 1991 |
Treatment of bone metastases from breast cancer and myeloma with pamidronate.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; D | 1991 |
Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases.
Topics: Administration, Oral; Bone Neoplasms; Diphosphonates; Drug Evaluation; Female; Humans; Middle Aged; | 1991 |
Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
Topics: Animals; Bone and Bones; Bone Neoplasms; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hyp | 1991 |
Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies?
Topics: Animals; Bone and Bones; Bone Neoplasms; Carcinoma 256, Walker; Diphosphonates; Drug Evaluation, Pre | 1990 |
Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate.
Topics: Administration, Oral; Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Drug E | 1990 |
[Establishment of a model to evaluate inhibition of bone resorption induced by bladder tumor (MBT-2) in mice].
Topics: Animals; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Models, Animal; Female; Mice; Neop | 1990 |
Radionuclide targeting of bone metastases: which efficacy?
Topics: Bone Neoplasms; Brachytherapy; Diphosphonates; Humans; Organophosphorus Compounds; Pamidronate; Radi | 1990 |
Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Infusions, Intravenous; Kidney; Neoplasms; Pa | 1989 |
Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases.
Topics: Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Diphosphonates; Humans; Male; Pamidronate; | 1989 |
Treatment of tumor-induced osteolysis by APD.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Rela | 1989 |
Single high dose aminohydroxypropylidene diphosphonate infusions to treat cancer-associated hypercalcaemia.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Diphosphonates; Female; Humans; Hypercalcemi | 1986 |
New inhibitors of osteolysis: implications for hypercalcemia and bone metastases.
Topics: Amifostine; Bone Neoplasms; Bone Resorption; Clodronic Acid; Diphosphonates; Humans; Hypercalcemia; | 1986 |
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Cyclic AMP; Diphosphonates; Female; Head and | 1986 |
Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma.
Topics: Bone and Bones; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Infusions, Intravenous; Os | 1988 |
Lytic bone metastases after APD in breast carcinoma.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Pamidronate | 1988 |
Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Middle Aged; Pamidron | 1988 |
[Bone metastases and hypercalcemia in cancer].
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcem | 1988 |
A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (APD) in the treatment of hypercalcemia of malignancy.
Topics: Bone Neoplasms; Calcium; Diphosphonates; Drug Administration Schedule; Female; Humans; Hypercalcemia | 1987 |
Distribution of 3-amino-1-hydroxypropane-1,1-diphosphonic acid in rats and effects on rat osteosarcoma.
Topics: Animals; Autoradiography; Bone Neoplasms; Diphosphonates; Electrolytes; Male; Neoplasm Metastasis; N | 1985 |
Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carcinoma 256, Walker; Diphosphonates; Male; Organop | 1986 |
Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma.
Topics: Animals; Bone and Bones; Bone Marrow; Bone Neoplasms; Diphosphonates; Male; Mice; Mice, Inbred C57BL | 1985 |